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This study was conducted to explore the suitability of the voltage gated potassium channel 
Kv10.1 as a novel therapeutic target in pancreatic ductal adenocarcinoma (PDAC). PDAC, 
which is characterized by marked invasiveness, rapid progression and profound resistance 
to therapy, accounts for more than 85% of pancreatic cancers and ranks fourth among 
cancer related deaths, having a 5-year survival rate of less than 5%. Ion channels are 
involved in many biological and cellular functions, also in the development of malignant 
phenotype. In particular, Kv10.1 is specially promising, because it is relatively tumour cell-
specific is aberrantly expressed in more than 70% of tumours from various origins. The two 
pancreatic cancer cell lines Capan-1 (high Kv10.1 expression, TRAIL insensitive) and 
BxPC-3 (low Kv10.1 expression, TRAIL-sensitive) were selected to test the efficacy of a bi-
functional construct consisting of a single-chain antibody specific to Kv10.1 fused to a 
soluble TRAIL mutant designed to bind equally to the two death- inducing TRAIL receptors 
DR4 and DR5 (Gly131>Lys; scFv62-TRAILLys). We chose to work with the first-line 
chemotherapeutic agent Gemcitabine to investigate if the construct would increase the 
sensitivity of the cancer cells towards the agent. In cytotoxicity and apoptosis assays, in 
combination with flow cytometry and live-cell imaging, Gemcitabine together with scFv62-
TRAILLys efficiently induced, apoptosis in both cell lines, outperforming both Gemcitabine 
alone and the combination with soluble TRAIL. After a 3 hour pre-treatment with 
Gemcitabine, an additional exposure of 3 hours with the construct was sufficient to trigger 
the maximum apoptotic effect. Evaluation of the treatment strategy on an in vivo tumour 
model demonstrated a significant reduction in tumour growth on treatment with the 
combination therapy compared to controls.  In conclusion, the results suggest that Kv10.1 
can be used as aim for a potential targeted therapy in pancreatic cancer both in vitro and in 






Anatomy and physiology of the pancreas 
 
 
The pancreas is an essential organ of endodermal derivation and is important for nutrient 
metabolism (protein, carbohydrate and glucose homeostasis) and has an exocrine and 
endocrine function.   
The exocrine part of the pancreas represents 80% of the organ tissue. It is made up of a 
network of acinar and duct cells. The acinar cells are organized in functional units that 
produce pancreatic juice containing zymogens, which is transported into the duodenum 
through the ductal system. Inside the acinar units near the ducts are centroacinar cells. The 
endocrine cells are independent and responsible for controlling the homeostasis of glucose 
by secretion of hormones into the blood stream.  The endocrine part of pancreas is made 
up of four specialized endocrine cell types that are clustered in so-called Islets of 
Langerhans (Shih et al. 2013). 
  




Pancreatic ductal adenocarcinoma 
 
Pancreatic ductal adenocarcinoma (PDAC), whose name derives from the histological 
similarity to ductal cells, accounts for 85% of all pancreatic cancers (Hezel et al. 2006). It is 
comparatively a rare disease accounting for 45,000 cases per year in the United states and 
the 11th most common cancer overall (Ryan et al. 2014). Globally it is the 4th leading cause 
of cancer-related deaths in both men and women (Bardeesy et al. 2002, Chu et al. 2007, 
Murtaugh 2014, Dunne et al. 2015). It has a 5-year survival rate of 3%-6% and median 
survival of less than 6 months that has not improved over 30 years (Murtaugh 2014, Dunne 
and Hezel 2015, Tanaka 2016). One of the main reasons for this lethality is the late 
diagnosis, by which time the disease has already infiltrated into the lymphatic system and 
metastasized to distant organs (Hezel et al. 2006). Complete pancreatectomy does not  
avoid reoccurrence (Murtaugh 2014). A recent study has estimated that the time between 
the first genetic ‘hit’ of PDAC and the invasive cancer is more than ten years and further 6 
years are required before the metastatic lesions are established (Murtaugh 2014). 
 
Epidemiology and risk factors of PDAC  
 
PDAC is associated with only a few dominant genetic conditions, demographic and 
environmental factors. Over the years various studies have shown a strong link between 
PDAC development and age, gender, smoking, alcohol consumption, chronic pancreatitis, 
diabetes, blood type and obesity (Hezel et al. 2006). It is rarely diagnosed in individuals 
younger than 40 years of age; its average age of diagnosis is 71 years (Bardeesy and 
DePinho 2002, Ryan et al. 2014).  It is 30% more common in men than women. This could 
be partly due to increased use of tobacco by men, because smokers show 75% increased 
risk, which persists for a minimum of 10 to 20 years after quitting (Muniraj et al. 2013). 
People who are obese have 20% greater risk of developing pancreatic cancer when 
compared to normal body weight individuals. Early age of onset of pancreatic cancer is 
particularly linked to abdominal obesity. A recent study showed that there is inverse 
correlation between the age of onset of diabetes and higher risk of developing PDAC. The 
relationship between alcohol and PDAC is unclear, although a recent meta-analysis linked 





Stromal biology of PDAC 
 
PDAC is characterized by a histologic hallmark known as desmoplastic/fibrotic reaction or 
stromal reaction. The stroma plays an intricate and dynamic role by relaying signals 
between cancer cell and resident cells (Pandol et al. 2009).  The stromal reaction is 
composed of both cellular and non-cellular components that provide a scaffold for the 
cancer cells to proliferate by providing growth factors and immune modulators (Fig. 1). The 
cellular components include pancreatic stellate cells (PaSCs), fibroblasts, immune cells, 
endothelial cells and nerve cells whereas the non-cellular components include extracellular 












Figure 2: Desmoplasia in PDAC. Pancreatic cancer cells and duct cells boost each 
other’s proliferation rate and regulate the accumulation of ECM deposition, angiogenesis 




The main ECM proteins abnormally increased are type I and V collagen and fibronectin 
(Mollenhauer et al. 1987). The amount and type of collagen in PDAC desmoplasia is similar 
to the one found in alcoholic chronic pancreatitis and tumour-associated chronic 
pancreatitis tissue (Pandol et al. 2009). The stroma has the capacity to modulate essential 
properties of tumour cells, including their metastatic properties. Various studies have also 
established that chronic inflammatory condition induces stromal activation similar to that of 
PDAC. Molecular events important for PDAC development, including K-Ras mutation or 
NFB activation, are also deregulated in chronic pancreatitis. In the recent past, Guerra et 
al. have demonstrated that chronic pancreatitis in adult mice driven by the K-RasG12V 
mutation can lead to the formation of a PDAC-like tumour (Guerra et al. 2007). PDAC 
desmoplasia and chronic pancreatitis are histologically very similar and have similar gene 
expression profiles. All these observations point towards a possible role for inflammatory 
environment contributing to nurturing a change of epithelial pancreatic cells towards a 
neoplastic phenotype, which may result in the development of PDAC (Hernandez-Munoz et 
al. 2008). Inflammation and tumourigenesis are closely connected from early stages of 
pancreatic injury, conveying that there is an essential need for better understanding of the 
stroma-parenchyma association in PDAC (Gukovsky et al. 1998, Lohr et al. 2005).  
Mast cells, macrophages, lymphocytes and plasma cells can be found at the edges of the 
tumour. It has been shown that there is an association between poor survival and high 
number of mast cells (Pandol et al. 2009). Interestingly, many patients with pancreatic 
cancer have tumour antigen-specific and functionally competent T cells in both peripheral 
blood and bone marrow that have a cytotoxic effect upon exposure to cultured pancreatic 
cancer cells in-vitro (Schmitz-Winnenthal et al. 2005). This suggests that the complex 
cancer microenvironment within PDAC could play a role in negating beneficial effects of 
these T cells and thereby protecting the cancer cells (Kleeff et al. 2007). PDAC is a 
hypovascular solid tumour, and even the few intratumoural blood vessels present are non-
functional. This limited number of blood vessels and dense fibrous stroma are pointed out 
to be among the reasons why systemic chemotherapeutic agents fail to deliver on their 





Pancreatic stellate cells (PaSCs)  
PaScs were discovered by Watari et al. (Watari et al. 1982) and have recently been shown 
to play a major role in desmoplasia of PDAC. They produce the major chunk of ECM as 
well as cytokines, chemokines and growth factors that play an important role in the 
development and progression of PDAC (Rucki and Zheng 2014). 
PaSCs are predominantly located in the periacinar space of the exocrine pancreas and 
comprise 4 to 7 % of total pancreatic parenchymal cells (Pandol et al. 2009, Wilson et al. 
2014). In these periacinar spaces they are in a quiescent state, characterized by long 
cytoplasmic processes that encircle the base of the pancreatic acinus. They are also found 
in the perivascular and periductal regions of the pancreas. In an inactive form they contain 
a prominent endoplasmic reticulum, collagen fibrils and vitamin A-containing lipid droplets 
that surround the nucleus (Apte et al. 1998). They also express desmin, glial fibrillary acid 
protein (GFAP), vimentin and nestin as well as neuro-ectodermal markers such as nerve 
growth factor (NGF) and neural cell adhesion molecules; the expression of these selective 
markers differentiates PaSCs from fibroblasts (Wilson et al. 2014). They also have low 
proliferation and ECM production rates during their quiescent state. PaSCs not only 
produce ECM proteins but also enzymes that degrade them (Metalloproteinases (MMPs)), 
and inhibitors of the same MMPs thereby playing a crucial role in the maintenance of 
normal pancreatic architecture (Wilson et al. 2014) .  
  
Figure 3: Schematic representation of tumour-stroma interaction during PDAC 




Acute injury of the pancreas leads to the activation of stellate cells, which secrete an 
excess of ECM proteins and builds a framework to regenerate epithelial cells. The 
activation of PaSCs at a cellular level is characterized by loss of lipid droplets and 
expression of alpha-smooth muscle actin (alpha-SMA) (Pandol et al. 2009). On healing, 
most activated PaSCs are lost through apoptosis. The few remaining active PaSCs start to 
secrete MMPs that degrade the excess fibrosis resulting in the return to normal pancreatic 
histology. However, if the injury is repeated or not healed the PaSCs retain their active form 
secreting cytokines and growth factors, in turn activating more PaSCs (Wilson et al. 2014). 
There is even a boost in the proliferation of mesenchymal cells such as interlobular 
fibroblasts or pericytes that contribute to the stromal composition with extensive deposition 
of ECM (Hernandez-Munoz et al. 2008). Additionally there is production of new blood 
vessels and infiltration of inflammatory cells into the stroma. This extensive deregulation 
can lead to the development of neoplastic lesions which further activates additional 
components of the stroma eventually leading to the development of PDAC (Chu et al. 
2007).  
Pancreatic cancer cells and PaSCs have a symbiotic relationship in PDAC that contributes 
to the aggressive growth of the tumour and possibly play a role in metastasis. Supernatant 
from human pancreatic cancer cell cultures have been shown to stimulate the proliferation 
and production of ECM by PaSCs. It has been reported that proliferation of PaSCs is driven 
by secreted platelet-derived growth factor and the ECM production by the activity of 
transforming growth factor-beta and fibroblast growth factor-2 (Apte et al. 2004, Bachem et 
al. 2005). The growth rate of tumour cells injected subcutaneously into nude mice increases 
in combination with PaSCs, and leads to the development of desmoplasia similar to the one 
seen in human PDAC patients (Bachem et al. 2005, Pandol et al. 2009). These factors are 
suggested to play a major role in the proliferation, migration, invasion and resistance to 
radiation and chemotherapy in PDAC tumours (Pandol et al. 2009).   
Extracellular Matrix (ECM)  
The non-cellular component of the stroma includes various fibrous proteins (collagen), 
polysaccharides (hyaluronan), and glycoproteins (fibronectin) and also growth factors. This 
stromal mesh, apart from providing support to the surrounding tissue also, plays a role in 
differentiation, remodeling and homeostasis in healthy organs (Frantz et al. 2010).  Some of 




expression levels of transgelin, which is associated with the activation of PSCs (Apte et al. 
2013).  The expression levels of collagen have been linked to resistance towards 
Gemcitabine, the current first line drug for PDAC. High stromal levels of Hyaluronan, a non-
typical glycosaminoglycan is able to retain water, increase intratumoural fluid pressure and 
thereby decrease the penetration of the drug into the tumour (Michl et al. 2012, Provenzano 
et al. 2012, Rucki and Zheng 2014). This, together with the hypovascular nature and the 
dense stroma are among the reasons for the failure of systemic chemotherapeutic agents 
and some newly tested antiangiogenic drugs in PDAC (Rucki and Zheng 2014). 
Immune cells  
Immune cells also participate in tumour progression, chemotherapy resistance and 
metastasis. It was first observed by Rudolf Virchow that leukocytes infiltrate tumour tissues 
indicating a connection between inflammation and cancer (Balkwill et al. 2001) and that 
chronic inflammation leads to the development of cancer. Among the inflammatory cells 
that infiltrate tumours and localize in the tumour stroma are tumour-associated 
macrophages (TAM), neutrophils and regulatory T cells (Treg).  
TAM’s are the majority of immune cells infiltrating the stroma or tumour microenvironment 
(Solinas et al. 2009). They are recruited by chemo-attractants, get activated upon reaching 
the tumour and secrete growth factors and cytokines that in turn alter the stroma and 
enhance the desmoplasia reaction (Apte et al. 1999). Activated TAMs stimulate PDGF 
expression in PaSCs driving their proliferation and the synthesis of collagen type I and 
fibronectin (Ross 1989, Schmid-Kotsas et al. 1999, Aoyagi et al. 2004).  
Neutrophils and Treg cells are the other types of immune cells that contribute to desmoplasia 
in PDAC.  Neutrophils along with TAMs play a role as phagocytes at the inflammation site 
and release toxic granules that are the source for ROS (reactive oxygen species) 
production. ROS in turn contribute to genomic instability (Toyokuni et al. 1995, Vaquero et 
al. 2004), and in some cases lead to stimulation of the non- enzymatic activation of TGFin 
vivo which in turn leads to the activation of PaSCs (Koli et al. 2008). Infiltrating neutrophils 
also regulate angiogenesis and ECM remodeling via expression of MMP-9 (Nozawa et al. 
2006). Treg cells play a major role in immune response to cancer by suppressing an effective 
response that the immune system may start. The increase in the frequency of Treg cells in 




2002, Liyanage et al. 2006). They also secrete TGFwhich provides an anti-inflammatory 
effect and contributes to suppressing auto immunity (Moore et al. 2001, Li et al. 2006, 
Miyara et al. 2007). 
 
Molecular genetics of PDAC 
 
Transformation from a normal cell to a tumourigenic one has been thought to involve six 
major steps. They do not have any specific order and can take place individually or in 
combination depending on the type of cancer. These steps include production of excessive 
growth factors, lack of response to antigrowth signals, escaping apoptosis, boundless 
replicative capability, continuous angiogenesis and finally metastasis or invasion (Hanahan 
et al. 2011). These molecular events have also been associated with PDAC development 
(Bardeesy and DePinho 2002, Hezel et al. 2006).  
  






KRAS is a well-known oncogene belonging to the RAS super family of GTP binding 
proteins involved in cell proliferation and growth. Point mutations at codon 12, 13, and 61 
(Muniraj et al. 2013, Ryan et al. 2014), near or at the catalytic site, leads to the inactivation 
of the GTPase activity site thereby constitutively activating KRAS signaling (Hezel et al. 
2006, Mihaljevic et al. 2010). Mutant KRAS is detected only in 30% of early stage 
pancreatic cancers (like the PanINs), but almost 100% of PDACs (Bardeesy and DePinho 
2002, Mihaljevic et al. 2010).  Constitutively active KRAS results in activation of the 
phosphoinositide 3 kinase (PI3K) pathway, related to cell proliferation and survival (Hezel et 
al. 2006).  
RAF/ERK is a family of serine/threonine kinases that are activated by RAS which leads to a 
series of phosphorylation events that ends in the activation of the mitogen activated protein 
kinase ERK.  A histological subtype of PDAC known as the medullar subtype lacks K-RAS 
mutation however has mutated B-RAF pointing to the inverse correlation between the two in 
PDAC.  
Hedgehog pathway is normally inactive in adult Pancreas however, found to be activated 
in PanIN lesions and increases through the progression to later stages of PDAC (Hezel et 
al. 2006, Mihaljevic et al. 2010, Dunne and Hezel 2015); transforming growth factor beta 
TGF-) pathway, whose downstream effector SMAD4 (Hezel et al. 2006) shows loss of 
heterozygosity (LOH) in 90% PDAC, and 50% of PDAC have either homozygous deletion 
or mutational inactivation of the second allele (Mihaljevic et al. 2010).  
Table 1: Commonly affected genes in PDAC and their frequencies (adapted  
 (Ottenhof et al. 2011) 
 Type Genes Function PDAC(%) 
 






























Wnt/-catenin pathway is associated with proliferation, morphogenesis and differentiation 
of several organs, including the pancreas (Clevers 2006). Aberrant activation of this 
pathway is seen in 65% of pancreatic cancers (Wormann et al. 2013).  
Notch signaling pathway is involved in guiding cell fate and cell proliferation during 
embryonic development of the pancreas and other organs (Mihaljevic et al. 2010). 
Activation of Notch signaling has been associated with the development of PanIN lesions 
linking it to initiation, progression and maintenance of pancreatic cancer (Mullendore et al. 
2009, Mazur et al. 2010, Ristorcelli et al. 2010). 
Tumour suppressor genes 
 
Table 2: Hereditary syndromes linked to increased risk to develop PDAC (Ottenhof et 
al. 2011) 
Syndrome Gene(s) Relative risk for PDAC 
Familial atypical multiple melanoma and mole 
syndrome 
CDKN2A/p16 20-34 
Peutz-Jeghers syndrome LKB1 >100 
Hereditary Pancreatitis PRSS1/SPINK1 ~90 
Familial Breast cancer BRCA2 3-10 
 
Various tumour suppressor genes have also been linked with PDAC development. 
Missense mutations in the DNA binding domain of P53, a tumour suppressor gene have 
been detected in >50% of PDAC cases. They are also commonly found in the later stages 
of PanINs that already possess a significant feature of dysplasia (Bardeesy and DePinho 
2002, Hezel et al. 2006). The LOH of CDKN2A (INK4A) gene through deletions or 
promoter hyper methylations are seen in about 80%-95% of PDAC cases (Hezel et al. 
2006). LKB/STK11 another tumour suppressor gene is normally involved in cell polarity, 
and metabolism however, also seen to be associated with PDAC (Su et al. 1999).  BRCA2 
gene is yet another tumour suppressor gene found to be associated with PDAC, whose 
loss in normal cells leads to an accumulation of pro-carcinogenic chromosomal alterations 
(Venkitaraman 2002). A mutation del6174T in this gene is particularly common in familial 
pancreatic cancer patients that have descended from the Ashkenazi Jewish population 




Apoptotic signaling pathways  
Recent studies have observed that 100% of pancreatic cancers possess alteration in 
apoptotic pathways. Anti-apoptotic proteins like the protein tyrosine phosphatase FAP-1 
and cellular FLICE-inhibitory protein (cFLIP) when overexpressed in PDAC cells protect 
them from apoptosis (Elnemr et al. 2001). Two other anti-apoptotic proteins that belong to 
the  BCL2-family members; BCLXL and MCL-1 have been observed to be over expressed, 
and pro-apoptotic protein BAX shows reduced expression in ~50% of PDAC cases (Evans 
et al. 2001, Magistrelli et al. 2006). Expression of decoy receptor 3 (that either lack or have 
an incomplete death domain which makes it impossible to induce apoptosis upon ligand 
binding in tumour cells could be another reason as it competes with the binding of FASL 
leading to the blocking of apoptosis initiation as they do not have an intact death domain 
(Elnemr et al. 2001).   
Growth factor receptor signaling 
Epidermal growth factor (EGF) receptors and ligands are over expressed in PDAC (Barton 
et al. 1991, Korc et al. 1992). Insulin-like growth factor (IGF) is over expressed in both 
tumour and stroma (Bergmann et al. 1995, Stoeltzing et al. 2003). Met is associated with 
metastasis in various cancers (Hezel et al. 2006) is expressed at low levels in the exocrine 
pancreas, but  up-regulated in PanINs and PDACs. (Ebert et al. 1994, Di Renzo et al. 1995, 
Paciucci et al. 1998). Fibroblast growth factor (FGF) signaling has been observed to 
contribute to mitogenesis and angiogenesis in PDAC. Over expression of bFGF contributes 
particularly to desmoplasia in primary tumours (Wagner et al. 1998, Ogawa et al. 2002, 
Kleeff et al. 2004). Vascular endothelial growth factor (VEGF) is also overexpressed in 
PDAC. Blocking of this pathway suppresses tumourigenic growth in pancreatic cancer 
xenografts (Itakura et al. 1997, Seo et al. 2000). 
Telomere shortening and dysfunction 
Telomere loss contributes to high occurrence of PDAC in conditions like advanced age or 
inflammatory like hereditary pancreatitis as a function of epithelial turnover.  In PanIN 
lesions shortened telomeres and anaphase bridging have been detected as an early 




















Pancreatic intraepithelial neoplasias (PanIN) (carcinoma in situ) 
PanINs are important and well known precursors that are thought to be the origins of 
PDAC. They are characterized by small flat microscopic asymptomatic lesions measuring 
<5mm arising in small intralobular pancreatic ducts (Brosens et al. 2015), not invasive and 
not crossing the basement membrane. PanIN are grouped into three grades of dysplasia: 
PanIN-1A (flat epithelium); PanIN-1B (papillary or micro papillary architecture, with low 
grade dysplasia), PanIN-2 (papillary epithelium with intermediate grade dysplasia and mild 
to moderate cytological atypia), and PanIN-3 (papillary cells with high grade dysplasia and 
Figure 5: Progression model of PDAC: From normal epithelial to low-grade PanIN, 
and to High-grade PanIN accompanied by the various genetic alteration. (Adapted from 




severe cytological and architectural atypia). PanINs are encircled by lobular parenchymal 
atrophy that can be detected by endoscopy and could act as a potential biomarker in 
patients for high risk of PDAC (Hruban et al. 2004, Brosens et al. 2015). Early genetic 
alterations include telomere shortening, K-RAS activation, inactivation of various tumour 
suppressor genes like p53 and p16 (CDKN2A) (Distler et al. 2014).   
 
Treatment strategies in PDAC 
 
Past and Present 
Gemcitabine has been known to be the keystone for the first-line therapy in PDAC 
treatment since 1997 as it showed clinical benefit. Prior to Gemcitabine, it was 5- 
fluorouracil (5-FU) that was administered in different doses and combination regime for 
palliative treatment of advance PDAC. Cochrane systematic review showed that 5-FU 
based treatment significantly increased the 6 and 12 month survival compared to supportive 
care and significant clinical benefit (Yip et al. 2006). Conversely, a phase III study by Burris 
et al showed Gemcitabine to be better than 5-FU in regards to the clinical benefit response 
(CBR) and in the secondary endpoint overall survival. Additionally it also showed that the 6-
, 9- and 12- month survival rate was higher with Gemcitabine than with 5-FU(Burris et al. 
1997).  Efforts have been made to improve the efficacy of Gemcitabine in combination with 
a second agent for example Erlotinib (EGFR tyrosine kinase inhibitor) that ended in a 
statistically significant improvement in overall survival in inoperable PDAC cases (Moore et 
al. 2007). Louvet et al has shown that when Oxaliplatin was added to Gemcitabine there 
was improved response rate (ORR), progression-free survival (PFS) and CBR compared to 
single treatment. However, no statistical significance in OS was seen (Louvet et al. 2005). 
While the combination treatment with Gemcitabine and Capecitabine showed a significant 
improvement in ORR but no increase in OS (Cunningham et al. 2009).  
FILFIRINOX treatment: Apart from Gemcitabine-based therapy, in the past few years a 
multi chemotherapy regimen FILFIRINOX has been employed as it was shown to have a 
significantly higher efficacy compared to standard single-agent Gemcitabine in a 
randomized multicenter phase II/III study (Conroy et al. 2011).  This regimen included a 




folinate, 400 mg/m2, 2 hour infusion), irinotecan (180 mg/m2 ,90 min infusion), 5-FU (400 
mg/m2 ,bolus) followed by a 5-FU (2400 mg/m2 infusion over 46 hours every 2 weeks). This 
study encompassed 342 patients with metastatic PDAC that were not treated with 
chemotherapy. In case of OS FOLFIRINOX group had 11.1 months as compared to 
Gemcitabine group with 6.8 months. And in case of median progression-free survival was 
6.4 month in FOLFIRINOX group as compared to 3.3 months in Gemcitabine group. In 31% 
of patients there was deterioration in the quality of life at 6 months in FOLFIRINOX group 
when compared to 66% of patients in Gemcitabine group. Some reports have showed an 
increase in toxicity this included neutropenia, febrile neutropenia, thrombocytopenia, 
diarrhea and sensory neuropathy with this treatment regimen (Conroy et al. 2011).  
Gemcitabine/NAB-Paclitaxel treatment: Nab-paclitaxel is a nanoparticle albumin-bound 
(nab) paclitaxel and it can be up taken by the cells that express SPARC (secreted protein 
acidic and rich cysteine)(Vaccaro et al. 2015).  In a phase III trial that had 861 metastatic Pc 
patients that received randomly nab-Paclitaxel (125 mg/m2 plus Gemcitabine (1000 mg/m2) 
or single agent Gemcitabine (1000 mg/m2). Results indicated a significant improvement in 
OS with nab-Paclitaxel plus Gemcitabine when compared to Gemcitabine alone. Even the 
ORR was significantly higher compared to Gemcitabine alone. In spite of this having a 
clinical improvement in efficacy, there were adverse effects from this regimen including 
fatigue, alopecia, nausea, neutropenia (Vaccaro et al. 2015).  
 
Future 
The main therapeutic intervention in relation to PDAC has been limited in most cases to 
chemotherapy drugs. The only targeted drug being used in clinic is erlotinib but as 
mentioned before is also in combination with Gemcitabine. Recent clinical trials on novel 
therapy towards PDAC have been ongoing in various places. Many of these are 
maintenance therapies whose ultimate aim is to maintain the progress achieved by first line 
therapies such as Gemcitabine treatment and delay tumour recurrence which in turn will 
provide an increase in overall survival (Vaccaro et al. 2015). Reni et al  documented a 
multicenter phase II study that encompassed 56 metastatic PDAC patients that were 
progression-free after 6 months from the start of first line chemotherapy, they were 




improvement in 6 month PFS.  It was also observed that the number patients that were 
alive at two years tripled under the maintenance therapy with Sunitinib (Reni et al. 2013).  
 
Kv10.1 (Voltage gated potassium channel) 
 
Kv10.1 (Eag1, Ether-á-go-go) is a voltage-gated potassium channel first identified in 
Drosophila melanogaster. The mammalian homolog has three sub families; eag (Kv10.1 
and Kv10.2), erg (eag related gene) (Kv11.1, Kv11.2 and Kv11.3) and elk (eag-like K+ 
channel). Each of them has been shown to have diverse electrophysiological properties 
(Kaplan et al. 1969, Warmke et al. 1991).   
Kv10.1 is mainly expressed in the brain among normal tissues at the transcript level. It is 
also expressed in myoblasts, placenta, testis and adrenal glands. Interestingly, it is 
aberrantly expressed in >70% tumours from various origins. Recently, studies on the 
expression of Kv10.1 especially in Hela cells and mouse embryonic fibroblasts have shown 
that the expression is coupled to cell cycle specifically at the G2/M phase in both these cell 
types (Pardo et al. 1999, Urrego et al. 2016).   
Molecular cloning studies suggested a structure made up of six putative transmembrane 
segments and a pore loop, which fits the basic frame of voltage-gated potassium channels.  
Kv10.1 is encoded by the gene KCNH1 located on chromosome 1q32.1-32.3, consisting of 
11 exons and large introns (Pardo et al. 1999). Various studies over the years have 
demonstrated the presence of alternatively spliced variants of Kv10.1, specifically in 
humans it is the E65 and E70 variants caused due to exon skipping (Pardo et al. 1999, 
Ramos Gomes et al. 2015). Kv10.1 induces malignant features including faster growth rate 
and loss of contact inhibition thereby promoting migration when overexpressed in cells in 
vitro  (Pardo et al. 1998). On the contrary, antisense oligonucleotides or siRNA, or 
pharmacological inhibitors like imipramine, astemizole or quinidine that inhibit Kv10.1 
expression or function result in a reduction in the rate of proliferation in vitro (Ouadid-
Ahidouch et al. 2001, Gavrilova-Ruch et al. 2002, Weber et al. 2006, Gomez-Varela et al. 
2007, Ouadid-Ahidouch et al. 2008, Martinez et al. 2015). In vivo experiments have 




mice (Pardo et al. 1999, Downie et al. 2008).  Similar to the in vitro studies, inhibiting the 
channel via the use of specific monoclonal antibody also demonstrate a reduction in the 
tumour growth in vivo (Gomez-Varela et al. 2007). Oral administration of astemizole a non-
specific blocker of the channel has also shown to have a negative effect on tumour 
progression and also a reduction of metastasis in lung carcinoma in vivo (Downie et al. 
2008, Garcia-Quiroz et al. 2012, Martinez et al. 2015).  
Kv10.1 plays an active role in tumour progression. In SHSY5Y cells, a commonly used 
neuroblastoma cell line, expression of Kv10.1 was shown to be indirectly controlled by p53 
(Lin et al. 2011) through the E2F1 transcription factor, suggesting that p53 inactivation 
frequent in cancers could lead to the abundant expression of Kv10.1 seen in most tumours. 
Estrogen receptors (ER) and human papillomavirus (HPV) oncogenes (E6/E7) could also 
play a role in regulating the expression of Kv10.1. Estrogens upregulate Kv10.1 expression 
in a cell type dependent manner, and Kv10.1 is highly expressed in HPV oncogene 
expressing cells (cervical cancer cells and infected keratinocytes) when compared to 
normal keratinocytes (Diaz et al. 2009). HPV oncoproteins E6 and E7 have an effect on cell 
proliferation through p53 and Rb proteins respectively. It has been shown recently in 
primary keratinocytes, that targeting of the p53 and pRB by these oncoproteins leads to the 
enhanced expression of Kv10.1 at the transcript level (Urrego et al. 2016). Recent studies 
have also demonstrated that Kv10.1 is regulated by the pRB/E2F1 pathway in cell cycle 
progression specifically the G2/M phase in various cells including cancer and normal 
proliferating cells  (Urrego et al. 2016).  In conclusion the voltage gated potassium channel 
Kv10.1 being expressed in most solid tumours including pancreatic cancer makes it not 





Apoptosis and cancer 
 
Programmed cell death or apoptosis occurs naturally in any multicellular organism as part 
of a normal physiology or as an anti-neoplastic mechanism in normal cells wherein, upon 
detection of alterations such as DNA damage, oncogene activation or cell cycle 
deregulation it induces programmed cell death so as to avoid the cell becoming 
tumourigenic (Hamacher et al. 2008). A major goal of cancer therapeutic research is to find 
a way to selectively kill cancer cells. Enormous work has been undertaken to discover a 
molecule that has an anti-cancer characteristic that will selectively induce apoptosis in 
cancer cells and not normal cells. Apoptosis is a cellular process that is characterized by 
distinct morphological characteristics as well as energy dependent biochemical 
mechanisms. The morphological features typically include cell shrinkage, chromatin 
condensation and cytoplasmic membrane blebbing whereas the biochemical changes 
include protein cleavage, protein cross linking and DNA breakdown (Hengartner 2000, 
Falschlehner et al. 2007, Prasad et al. 2014). 
  
Figure 6: Apoptotic pathway: Intrinsic pathway (Mitochondrial pathway) and 





Apoptosis can occur either through the extrinsic pathway, which is mediated via the tumour 
necrosis factor (TNF) receptor super family, or the intrinsic pathway, which involves the 
mitochondria and is initiated and regulated by the Bcl2-protein family. Both these pathway 
activate ‘initiator caspases’ which subsequently activate the ‘effector caspases.  
The extrinsic pathway is triggered by death receptors on the cell surface (DRs). They 
belong to the Tumour-Necrosis Factor (TNF) receptor superfamily and include TNF-, FAS 
(APO-1, CD-95) and TRAIL (TNF-related apoptosis inducing ligands) receptors. The 
caspase cascade is activated through the trimerization of death receptors that lead to 
formation of death-inducing signaling complex (DISC). Binding of a ligand to one of the 
receptors leads to the transmission of apoptotic signals via the recruitment of Fas-
associated death domain protein (FADD), and activation of caspase-8 resulting in cleavage 
and activation of caspase-3, leading the cell to apoptosis.  
The effector caspases once activated lead to the destruction of the protein scaffold and cell 
membrane by proteolytic cleavage. When the cleavage and inactivation of ICAD/DFF45 
occurs by a caspase, it allows the caspase-activated DNase (CAD) to enter the nucleus 
and fragment the DNA leading to a DNA ladder characteristically seen in apoptotic cells 
(Widlak 2000).  
 
TRAIL  
TRAIL (TNF-related apoptosis inducing ligand) (Wiley et al. 1995, Pitti et al. 1996) is a 
cytokine involved in inflammation, apoptosis, proliferation, invasion, angiogenesis, 
metastasis and morphogenesis (Aggarwal et al. 2012). TRAIL is commonly expressed in 
immune cells where it plays a role in the homeostasis of T cells and in NK and T-cell- 
mediated killing of transformed cells (Falschlehner et al. 2007).  TRAIL is expressed in 
various tissues and cell types including thymus, lung, liver, placenta, ovary, heart, small and 
large intestine (Prasad et al. 2014). It is a 20kDa type II membrane glycoprotein, whose C 
terminus is proteolytically cleaved to give rise to soluble TRAIL. Both the full-length and 
soluble form of TRAIL can induce apoptosis in cancer cell lines (Trivedi et al. 2015).  
TRAIL is unique in the TNF super family as it interacts with an intrinsic receptor system that 
consists of two agonistic or apoptosis-inducing receptors which contain an intracellular 




(Falschlehner et al. 2007). Two anti-agonistic or decoy receptors DcR1 (no death domain) 
and DcR2 (truncated non-functional form of death domain) are also present; they not only 
fail to transmit apoptotic signal but also compete with the ligand-receptor binding complex 
thereby inhibiting TRAIL signaling. The fifth receptor is the soluble protein Osteoprotegrin 
(OPG) which has a low affinity towards binding to TRAIL (Trivedi and Mishra 2015).  
 
TRAIL death inducing signaling 
 
 
The activation of caspase-8 at the DISC results in the cleavage and autocatalytic activation 
of caspase-3 and BH3-only protein triggering caspase cascade and leading to apoptosis via 
extrinsic pathway (Jones et al. 2008). The activated and cleaved BID binds to BAX and 
BAK that results in mitrochondrial membrane permeabilization and releases cytochrome c 
protein and DIABLO. Cytochrome c and apoptotic protease-activating factor 1 (APAF1) and 
caspase-9 combine with ATP to produce a functional apoptosome and cleave caspase-9 
Figure 7 : Tumour Necrosis Factor (TNF) – related inducing ligand (TRAIL) 




which cleaves caspase-3 resulting in apoptosis. However, this activated caspase-3 also can 
cleave and activate caspase-8 resulting in more apoptotic signal (Jones et al. 2008). 
 
Non apoptotic TRAIL signaling 
Interestingly TRAIL signaling not only leads to the activation of initiator and effector 
caspases but also induces non-apoptotic pathways including activation of NFB, and 
MAPKs thereby enhancing cell development and proliferation. It has been reported that 
both TRAIL R1 and R2 receptors can induce non-apoptotic signaling leading to survival, 
proliferation, invasion and metastasis (Falschlehner et al. 2007). NF-B activation plays a 
role in innate and adaptive immunity, development, apoptosis and proliferation 
(Falschlehner et al. 2007). TRAIL activates NF-B via TRAIL-R1 and TRAIL-R2 and TRAIL-
R4 (Degli-Esposti et al. 1997, MacFarlane 2003). TRAIL-R1 and TRAIL-R2 has been 
shown to activate the protein kinase B (PKB)/Akt and MAPK; when ERK is activated it leads 
to the suppression of TRAIL-mediated apoptosis and inhibits the activation of pro-caspase-
8 and Bid (Soderstrom et al. 2002, Tan et al. 2009).  
 
Bi-functional antibody specific to Kv10.1 fused to apoptosis inducing 
sTRAIL 
 
It was Paul Ehrlich who depicted the future for antibodies as ‘magic bullet’ that would 
specifically kill microbes and tumour cells. Over the last 15 years several therapies 
involving antibodies have been established as successful strategies for treating patients 
with both hematological and solid tumours (Schrama et al. 2006). Single chain antibodies 
(scFv) have awakened interest because they are smaller in size and can penetrate faster 
and deeper into tumours, and are also less immunogenic compared to whole antibodies.  
In a recent study a bi-functional antibody implementing Kv10.1 as a tumour marker fused to 
sTRAIL was designed, engineered and tested on prostate cancer models. The construct 
induced apoptosis in both Kv10.1-positive and neighboring Kv10.1-negative cells 
(bystander effect) and had no effect on surrounding normal prostate epithelial cells 




two receptors is more relevant remains controversial as it appears to depend on the tumour 
type (Ichikawa et al. 2001, Almasan et al. 2003, Kelley et al. 2005, MacFarlane et al. 2005, 
Szegezdi et al. 2006). To broaden the spectrum of target tumours, it would be possible to 
generate a TRAIL variant capable of activating both DR4 and DR5 equally (Reis et al. 










To investigate and characterize the functional role of Kv10.1 in PDAC and its 
possible use as therapeutic target with a bi-functional anti-Kv10.1 antibody 
fused to a TRAIL variant, alone or in combination with Gemcitabine.




Table 3. Cell culture   




Cat no 14190-094 
Fetal bovine serum PAA  
Cat no A15-151 
Trypsin/EDTA Merck Biochrom 
Cat no L2123 
DMEM/ F-12 (1:1) 
GlutaMAX supplement 
ThermoFisher Scientific 
Cat no 10565-018 
Iscove’s Modified Dulbecco’s 
Media (IMDM) (1x) 
GlutaMAX supplement 
ThermoFisher Scientific 
Cat no 31980-022 
Panserin C6000 PAN Biotech 
Cat no PO4-716000 
OptiMEM ThermoFisher Scientific 
Cat no 31985-070 
Lipofectamine 2000 ThermoFisher Scientific 
Cat no 11668027 
Lipofectamine LTX and Plus 
Reagent 
Invitrogen  
Cat no 15338-100 
Lenti-X P24Rapid titer kit Clontech  
Cat no 632200 
Lenti-X packaging mix Clontech 
Cat no 631259 
 
Table 4. Cell based assays I 
kits and plates Supplier Purpose  
CytoGLO Annexin V-FITC  
Apoptosis Detection Kit 
Imgenex 
Cat no 10085K 
Cell surface expression of 
PS 
Caspase 3/7 apoptosis  
assay reagent (5mM) 
Essen Bioscience 
Cat no 4440 
Kinetic activation of 
Caspase-3/7 
CellToxTM Green Cytotoxicity Assay  
 
Promega 
Cat no G8741 
Detrimental effect of the 
compound  
Annexin V Green reagent Essen Bioscience 
Cat no 4642 
Cell surface expression of 
PS  
Human IL-8 Chemiluminescent  
ELISA 
Thermo scientific 
Cat no 84774 
Secretion of IL-8 
QCM 96 well Cell invasion  
Assay 
Millipore 
Cat no ECM555 
Invasion Assay 
CytoSlect  24-well cell migration  
assay(8 µm, Colorimetric Format) 
Cell biolabs 
Cat no CBA-100-5 
Migration Assay 
Ultra Low attachment multi well plates 
Round bottomed plate (7007) 
Corning 
Cat no CLS7007-24EA 
3D Cell culture 
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Table 5. Cell based assays II 
Agents Supplier 
Gemcitabine Sigma 
Cat no G6423-10MG 
TRAIL, Recombinant, Human 
(TNF-Related Apoptosis inducing ligand) 
US Biological life sciences 
Cat no T8180-08A 
Z-VAD-FMK (General caspase Inhibitor) R&D systems 
Cat no FMK001 
Astemizole Tocris 
Cat no 3489 
G418 Gibco 
Cat no 11811-031 
Puromycin ThermoFisher Scientific 
Cat no A11138-03 
Zeocin InvivoGen 
Cat no ant-zn 
Matrigel basement membrane mix Corning 
Cat no 4272006 
 
Table 6. Molecular biology I 
Kits and Reagents Supplier 
Pierce BCA Protein Assay Kit ThermoFisher Scientific 
Cat no 23225 
BSA Sigma 
Cat no A9418-100MG  
Non Fat Dry Milk BIO RAD 
Cat no 170-6404 
cOmplete, ULTRA, Mini, EDTA free, EASYpack 
Protease inhibitor cocktail tablets 
Roche 
Cat no 05 892 791 001 
Prestained Protein Ladder, Broad Range  
(10-230KDa) 
New England BioLabs 
Cat no P7710S 
NuPAGE Novex 4%-12% Bis-Tris Protein Gel 
1.5mm, 10 well 
ThermoFisher Scientific 
Cat no NP0335BOX 
NuPAGE Sample reducing agent (10x) Novex by Life technologies 
Cat no NP0009 
NuPAGE LDS sample buffer (4x) Novex by Life technologies 
Cat no NP0007 
NuPAGE MOPS SDS running buffer (20x) Novex by Life technologies 
Cat no NP0001 
Nitrocellulose  Pre-Cut blotting Membrane 
0.2µm pore size 
ThermoFisher Scientific 
Cat no LC2000 
Amersham Protran supported 
 0.45mm NC 
GE Healthcare life science 
Cat no 10600016 
Quentix Western Blot Signal Enhancer Kit ThermoFisher Scientific 
cat no 21050 
Western blocking reagent Roche 
cat no 11921681001 
Pierce ECL Western blotting substrate ThermoFisher Scientific 
cat no 32106 
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Table 7. Molecular biology II 
Antibody  Dilution Supplier 
Cleaved caspase-3 (Asp175) 
 
1:1000 Cell signaling 
Cat no 9661 
Actin (C-11) 1:1000 Santa Cruz 
Cat no1615 
Rabbit Anti Goat IgG 
(H+L)+HRP Conjugate 
1:1000 BioRad 
Cat no 172-1034 
9391 (polyclonal antibody Kv10.1) 1:1500 
1:2000 
L.A. Pardo; (Napp et al., 
2005) 
Anti-Glyceraldehyde-3-Phosphate 




cat no MAB374 
Amersham ECL Anti-rabbit IgG, 
Horseradish peroxidase-linked species-
specific whole antibody (from Donkey) 
1:1000 
1:2000 
GE Healthcare life science 
Cat no NA934 
Amersham ECL Anti-mouse IgG, 
Horseradish peroxidase-linked species-
specific whole antibody (from Sheep) 
 
1:10000 
GE Healthcare life science 
Cat no NA931 
Monoclonal anti-alpha Tubulin  
clone DM1Av 
  1:1000 Sigma Aldrich 
cat no T9026 
Goat anti-Mouse IgG1 Secondary 
Antibody, Alexa Fluor  488 conjugate 
1:1000 Thermo scientific 
Cat no A-21121 
 
Table 8. Kits and reagents 
 Reagents Supplier 
NucleoBond Xtra Midi EF Macherey Nagel 
Cat no 740420.50 
Taq DNA polymerase with ThermoPol Buffer New England Biolabs 
Cat no M0267S 
RNeasy Mini Kit Qiagen 
Cat no 74106 
RNase-Free DNase set Qiagen 
Cat no 79254 
SuperScript First-Strand Synthesis System Invitrogen 
Cat no 18080-051 
Ribonuclease H Invitrogen 
Cat no 18021-071 
Deoxynucleotide (dNTP) Solution mix BioLabs 
Cat no N0447S 
SuperScript II Reverse Transcriptase Invitrogen 
Cat no 18064-022 
1kb DNA Ladder BioLabs 
Cat no N3232S 
TaqMan PCR Reagent Kit Applied Biosystems 
QuikChange Site-Directed Mutagenesis Kit  
 
Stratagene  
Cat no 200518 
Human TRAIL/TNFSF10 Immunoassay Quantikine ELISA 
Cat no  DTRL00 
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Table 9. Primer (Nested PCR) 
 
Table 10. UPL Probes (Real-time PCR) 
ID 5´-Sequence-3´ Gene 
F 5´-TTG AGA AAA CAA TGC AAA ATG TG-3´  
Human transferrin receptor 
(TFRC) 
R 5´- CCC AGT TGC TGT CCT GAT ATA GA-3´ 
UPL 5´-FAM- CTG GGC AA -Dark Quencher Dye-3´ 
F 5´-TGA GGT GGT GGC CAT TCT A -3´  
Human Kv10.1 (KCNH1) R 5´- GGC CCT AAC ATT GGC ACA -3´ 
UPL 5´-FAM- TTG CCC AG -Dark Quencher Dye-3´ 
F 5´-GGG TCC ACA AGA CCT TCA AGT-3´  
Human TRAIL receptor 1 
(TNFRSF10A) 
R 5´- TGC AGC TGA GCT AGG TAC GA-3´ 
UPL 5´-FAM- TCC TGC TG -Dark Quencher Dye-3´ 
F 5´-AGA CCC TTG TGC TCG TTG TC -3´  
Human TRAIL receptor 2 
(TNFRSF10B) 
R 5´- TTG TTG GGT GAT CAG AGC AG -3´ 
UPL 5´-FAM- TCC TGC TG -Dark Quencher Dye-3´ 
F 5´-TTG AGA AAA CAA TGC AAA ATG TG-3´  
Human TRAIL 3 (TNFRSF10C) R 5´- CCC AGT TGC TGT CCT GAT ATA GA-3´ 
UPL 5´-FAM- CTG GGC AA -Dark Quencher Dye-3´ 
F 5´-TGA GGT GGT GGC CAT TCT A -3´  
Human TRAIL 4 (TNFRSF10D) R 5´- GGC CCT AAC ATT GGC ACA -3´ 
UPL 5´-FAM- TTG CCC AG -Dark Quencher Dye-3´ 
 
Table 11. Taqman Probes (Real-time PCR) 
 5´-Sequence-3´ Gene 
F 5´-TCT GTC CTG TTT GCC ATA TGA TGT-3´  
Human Kv10.1(KCNH1) 
  
R 5´-CGG AGC AGC CGG ACA -3´ 
Taq 5´-FAM AAC GTG GAT GAG GGC ATC AGC 
AGC CT- Tamra-3´ 
F 5’-GAC TTT GGA TCG GTT GGT GC-‘3  
Human transferrin receptor 
(TFRC) 
R 5’-CCA AGA ACC GCT TTA TCC AGA T-‘3 
Taq 5’-JOE-TGA ATG GCT AGA GGG A-Tamra dT-
ACC TTT CGT CCC-‘3 
 
  
Primer name Sequence (5’-3’) 
KV10.1 External Forward TGT TCG GCG GTC CAA TGA TAC TAA 
KV10.1 External Reverse TCC CGG CCC CCT CTC TCA 
KV10.1 Internal Forward TTG GGG AAT GCT CAG ATA GTG G 
KV10.1 Internal  Reverse GGC CTC ATT CTT TCG TTT CAT 
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Table 13. Equipment 
Equipment Supplier 
Microscope Axiovert 100 Carl Zeiss 
Megafuge 1.0 Heraeus Sepatech 
Centrifuge 5415D (Table-centrifuge) Eppendorf 
Centrifuge  5402 (Cooling-centrifuge) Eppendorf 
Victor2 1420 Multilabel counter Wallac 
Mastercycler gradient Eppendorf 
Thermomixer comfort Eppendorf 
NuPAGE Bis-Tris Electrophoresis System Invitrogen 
Incubator Heraeus instruments 
FACSaria cytometer BD Bioscience 
Spectrophotometer Implen 
pH meter Knick, pH-Meter 766 Calimatic 
ChemiDoc XRS system BioRAD 
GelDoc BioRAD 
LightCycler 480 Real-Time PCR System Roche 
Water Purification System Sartorius 
             IncuCyte ZOOM system                    Essen Biosciences 
 
  





1.0  Cell culture  
 
1.1 Cell lines 
 
PDAC cell lines were obtained from ATCC.  Capan-1(HTB-79) cells were grown in 
IMDM(1x)+ GlutaMAX  (GIBCO/Invitrogen) medium supplemented with 20% FCS (PAA 
Gold). AsPC-1(CRL 1682) and BxPC-3 (CRL-1687) in RPMI-1640 (GIBCO/Invitrogen) 
medium supplemented with 10% FCS (PAA Gold). MIA PaCa-2 (CRL 1420) in 
DMEM/F12 (1:1)(1x) GlutaMAX medium supplemented with 10% FCS (PAA Gold) and 
2.5% horse serum: PANC-1(CRL1469) in GlutaMAX medium supplemented with 10% 
FCS (PAA Gold). 
Immortalized pancreatic stellate cells RLT-PSC were generously provided by Dr. Ralf 
Jesnowski. These cells were grown in DMEM/F12 (1:1)(1x) GlutaMAX medium 
supplemented with 10% FCS (PAA Gold).  
CHO-K1 (Chinese hamster ovary) cells (ACC 110) were obtained from DSMZ and 
grown in Ham’s F-12 (GIBCO/Invitrogen) medium supplemented with 10% FCS (PAA 
Gold).  
Cells were cultured in 5% CO2 and a humidified atmosphere at 37 
oC. For sub culturing 
the cells were washed with Dulbecco’s phosphate buffered saline (DPBS, 
GIBCO/Invitrogen), after which they were incubated with Trypsin/EDTA (0.05%/0.02% 
W/V, Biochrom) in PBS for 4 min at 37 oC. Once the cells were detached the enzymatic 
reaction was stopped by addition of culture medium supplemented with FCS.  The 
detached cells were collected in a 15 ml falcon tube with fresh pre-warmed medium and 
washed at 235 x g for 2 min. The pellet of cells was further re-suspended in fresh pre-
warmed complete medium.  
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1.2 Cell counting 
This was performed using a mixture of cell suspension and trypan blue (0.4% solution). 
The cells were counted on a Neubauer counting chamber under light microscope. 
1.3 Cryopreservation and storage of cell lines 
The freezing medium contained 40% medium, 50% FCS, and 10% DMSO. Cells were 
pelleted, re-suspended in freezing medium and frozen in 1 ml aliquots containing 1x106 
– 2x106 cells per cryotube.  Cryotubes were then placed at -80o C in a container filled 
with isopropanol to ensure a constant decrease in the temperature at a rate of 1 oC per 
minute. The cryotubes were stored in liquid nitrogen. 
1.4 Thawing of cell lines 
As the frozen cells were in DMSO, which is toxic to the cell, thawing was done as 
quickly as possible. The frozen vials of cells were thawed in a water bath at 37 oC for 
approximately one min. The suspension of cells was pipetted into a 30 ml tube 
containing 10 ml pre-warmed medium and centrifuged at 235 x g for 2 min. The 
supernatant was aspirated and the pellet was re-suspended in fresh medium 
supplemented with FCS and plated into a culture flask.  The flask was then placed in 
the incubator for 24 hours after which the medium was changed.  
 
2.0  RNA isolation 
 
RNeasy Mini Kit (Qiagen) was used to isolate RNA.  Briefly, cells were lysed in the 
presence of guanidine thiocyanate-containing buffer, which inactivates RNases and 
thus assures the integrity of the purified RNA. The lysate was transferred into 
QIAshredder spin column (Qiagen) and centrifuged at 16100 xg for 2 minutes to shear 
genomic DNA and reduce viscosity. The homogenized lysate was mixed in a 1:1 
proportion with 70% ethanol and then transferred into the RNeasy mini column 
(Qiagen), followed by centrifugation at 8000 xg for 50 s. DNase digestion was 
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performed using the RNase-free DNase Set (Qiagen) to remove the DNA in the ratio of 
20 µL of DNase and 140 µL of RDD buffer (undisclosed composition; used to optimize 
on column DNase digestion) per column and incubated for 30 minutes at room 
temperature.  It was then washed twice (500 µL/wash) with buffer RPE (proprietary 
composition; a mild wash buffer) and centrifuged at 8000 x g for 50 s to remove 
contaminants. Finally, the RNA was eluted from the silica membrane by adding RNase 
free water followed by centrifugation. The purified RNA samples were stored at -80°C 
until use. 
2.1 cDNA Preparation 
The reverse transcription of total mRNA was performed using SuperScript III First-
strand synthesis system (Invitrogen).  Retro transcription was carried out by mixing 2.5 
μg of total mRNA, 12 μL of RNase-free water, and 1 μL of 50 μM oligo (dT), and 
incubating at 70°C for 10 min. The mixture was placed on ice for 1 min to allow primer 
annealing, and the RNA-primer mix was adjusted to 20 μL final volume for the cDNA 
synthesis, containing 1x RT (reverse transcriptase) buffer, 2.5 mM MgCl2, 10 mM DTT, 
0.5 mM dNTP mix and 10 U/μL SuperScript III RT. The mixture was incubated at 42°C 
for 50 min, followed by 15 min incubation at 70°C to stop the reaction. Afterwards, 1 μL 
RNase H (2U/ μL) was added to the mixture and incubated at 37°C for 20 min to 
eliminate any trace amounts of RNA. Finally, the cDNA volume was made up to 25 μL 
with water to get a final concentration of 0.1 μg/μL. 
2.2  Polymerase chain reaction 
PCR reactions were performed using 10 ng template plasmidic DNA (or 100 ng first 
strand cDNA), 2.5 µL 10X reaction buffer (containing 20 mM Tris-HCl, 10 mM 
(NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1% Triton X-100, pH 8.8; from New England 
Biolabs), 200 µM dNTP mix (New England Biolabs), 0.2 µM of specific primers 
(synthesized by Sigma), 1.2 U of Taq DNA polymerase (New England Biolabs) and 
sterile H2O to make a final volume of 25 µL. The thermocycler (Mastercycler, 
Eppendorf) was set up using the following amplification program:  
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Segments Cycles Temperature Time 
1 20 95°C 3 min 
  95°C 30 sec 
  69°C 1 min 
  72°C 3min 
Nested PCR reactions were performed using 150 ng first strand cDNA, 2.5 µL 10X 
reaction buffer (containing 20mM Tris-HCl, 10mM (NH4)2SO4, 10 mM KCl, 2mM MgSO4, 
0.1% Triton X-100, pH 8.8), 200µM dNTP mix, 0.2 µM of each specific primer (Ref 
Table 6), 1.2 U of Taq DNA polymerase and sterile H2O, up to 25 µL final volume. 1 µL 
of the first PCR product as template for the second round of PCR was used. The 
second PCR was carried out using the following amplification program:  
Segments Cycles Temperature Time 
1 35 95°C 3 min 
  95°C 30 sec 
  65°C 2 min 
  72°C 3min 
The amplification products were loaded on a 1.2 % agarose gel containing 5 µL (for 
each 100 ml gel volume) Serva DNA stain G (SERVA). Electrophoresis was performed 
at 100 V for ~40 min; the electrophoretic mobility was visualized with UV light. 
2.3  Quantitative real time PCR  
TaqMan assay (fluorescent donor: quencher hybridization) 
Gene expression in Capan-1, BxPC-3 and RLT-PSC were assessed by quantitative 
real-time PCR (qRT-PCR). qRT-PCR was performed using specific TaqMan sets in a 
Light Cycler 480 (Roche Applied Science) detection system. For the qRT-PCR reaction, 
2 μL of cDNA was mixed with 1 μL of 100 μM primer mix, 0.1 μL of 10 μM Universal 
Probe Library probe (Roche), and 0.1 μL Uracil-DNA-glycosylase 2 U/ μL (New England 
BioLabs). Afterwards, 5 μL of ready-to-use hot-start PCR mix (Roche) containing 
FastStart Taq DNA Polymerase reaction buffer, and dNTPmix were added.  
LightCycler 480 (Roche Applied Science) detection system was programmed  




Segments Cycles Temperature Time 
1  50°C 2 min 
  95°C 10 min 
  95°C 10 sec 
        50 56°C 1min 
  60°C 1 min 
  40°C 30 sec 
UPL probes 
Segments Cycles Temperature Time 
1  50°C 2 min 
  95°C 10 min 
  95°C 10 sec 
        45 60°C 30 sec 
  40°C 10 sec 
Relative quantification of the samples and human calibrator was done using the ΔΔCt 
method (Livak & Schmittgen, 2001); the human housekeeping gene transferrin receptor 
was used for normalization. 
3.0  Site-directed mutagenesis  
The Quick-change site-directed Mutagenesis Kit (Stratagene) was used to create point 
mutations in pSecTagscFv62-TRAIL plasmid (provided by Dr. Franziska Hartung) with 
the primer set (refer Table 12). The site-directed mutagenesis method was performed 
with complementary primers containing the mutation and the PfuTurbo polymerase. 
During temperature cycling the oligonucleotides generate the mutated plasmid. DpnI is 
used to digest the methylated parental DNA template and to select for mutation-
containing synthesized plasmid. The digested DNA was then transformed into E.coli 
XL1-Blue cells (see below).  
QuikChange mutagenesis PCR (50 μL) reaction consisted of 5 μL 10x reaction buffer, 
100ng DNA, 125 ng forward primer, 125 ng reverse primer, 1 μL of dNTP mix and H2O  
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Segments Cycles Temperature Time 
1 1 95°C 30 sec 
2 18 95°C 30 sec 
  55°C 1 min 
  68°C 1min/1kb plasmid 
3.1  Transformation of bacteria  
An aliquot of competent bacteria was thawed on ice and incubated with 100 ng plasmid 
DNA. Following the incubation on ice for 30 min, a heat shock at 42 °C for 45 sec was 
performed for the purpose of the plasmid to be taken up by the cells chemically. After 
which a 2 min incubation on ice is performed and 500 μL LB-medium was added and 
further incubated for 1 h at 37°C with gentle agitation. Finally, cells were plated on LB-
agar plates containing appropriate antibiotics and grown overnight at 37°C. 
3.2  Plasmid DNA purification 
pBRY-nuclear mCherry-IRES-PURO (plasmid # 52409 from Addgene) 
pSecTagscFv62-TRAILLys   (Backbone from Invitrogen and cloned in the laboratory) 
Non-Silencing-GIPZ lentiviral shRNAmir control (Glycerol stock) (ThermoScientific cat 
no RHS4346) 
To isolate single colonies from a stab culture, the bacteria were spread over one third of 
an LB-agar plate (with 100 µg/ml Ampicillin) using an inoculating loop, which was then 
sterilized and used to spread the bacteria onto the next one-third section of the plate 
and so on. The plate was incubated at 37 °C overnight (12 hours). Next day single 
colonies were spotted. With the help of a sterile pipette tip, a single colony was picked 
and dropped into 5 ml of liquid LB with 100 µg/ml Ampicillin in a 15 ml loose-capped 
conical bottom tube. This was incubated at 37 °C for 12 hours in a shaking incubator. 
Next day it was checked for bacterial growth that was characterized by a cloudy haze in 
the medium. 
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3.3  Endotoxin-free (EF) plasmid DNA purification 
The bacterial cells were harvested by centrifugation at 4500 xg for 15 minutes at 4 oC. 
The cell lysis was done by re-suspending the bacterial cell pellet in 8 ml of RES-EF 
(Resuspension buffer) buffer and allowed to sit at room temperature for 5 min. To 
equilibrate the NucleoBond Xtra column filter, 15 ml of buffer EQU-EF (Equilibration) 
was pipetted along the side of the column. The cell lysis reaction was neutralized after 
15 minutes by adding 8 ml of buffer NEU-EF (Neutralization buffer) and mixed gently by 
inverting 10-15 times. Next the lysate was loaded on to the NucleoBond Xtra column 
filter. The lysate was allowed to pass through the column, after which it was washed 
with 5 ml of FIL-EF (Filter Wash) buffer and allowed to pass through. Once that was 
done the NucleoBond Xtra column filter was discarded. The column was washed a 
second time with 35 ml of ENDO-EF and followed by a third time with 15 ml of WASH-
EF. Once this was allowed to completely flow through, the elution was performed with 5 
ml of ELU-EF (Elution) buffer. The next step was to precipitate the flow through with 3.5 
ml of Isopropanol which was centrifuged at 5-15000 x g for 30min at 4 oC. The DNA 
pellet was washed with 2 ml of 70% ethanol, centrifuged at 15000 x g for 5 minutes and 
dried. The DNA pellet was reconstituted with appropriate volume of H2O-EF. 
3.4  Concentration of DNA and RNA 
The concentration of both RNA and DNA as well as the purity of the DNA was 
measured spectrometrically using a NanoDrop instrument at 260 nm. Any sample that 
had a 260 nm/280 nm readout less than 1.8 or more than 2 were discarded.  
cDNA (µg/ml) = A260 x 50  
cRNA (µg/ml) = A260 x 40  
3.5  Transfection  
DNA transfection was performed using Lipofectamine LTX and Plus Reagent 
(Invitrogen) (according to the user manual) with 2 g of DNA for the two plasmids for 
respective cell lines was used along with the reagent in opti-MEM medium. It was 
incubated for 4 hours and replaced with normal medium containing 10 % FCS.  
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Tube 1 2  μg DNA 7,5 μL Plus Reagent 500 μL OptiMEM 
Tube 2 30 μL Lipofectamine 1 ml OptiMEM  
It was allowed to stand for 5 min at room temperature, meanwhile replacing the 
complete medium from the T25 flask to 3 ml of OptiMEM medium. The mixtures from 
the two tubes were added to the cells followed by further incubation for 4 hours in the 
incubator. Change the medium to the complete medium and for stably transfected cell 
lines appropriate antibiotics were used after 24 of transfection.  
 CHO-K1 (pSecTagscFv62-TRAILLys ) - zeocin (500 g/ml)  
 RLT-PSC (pBRY-nuclear mCherry-IRES-PURO) - Puromycin (0.5g/ml) 
SiRNA transfection was performed using Lipofectamine 2000 (Invitrogen) (according to 
the user manual) with 30 nM SiRNA control and SiRNA Kv10.1 along with 
Lipofectamine 2000 in opti-MEM medium. It was incubated for 4 hours and replaced 
with normal medium containing 10 % FCS.  
Tube 1 30nM SiRNA 500 μL OptiMEM 
Tube 2 15 μL Lipofectamine 2000 500 μL OptiMEM 
The two tubes were allowed to stand at room temperature for 5 min and followed by 
mixing them together and incubated for 15 min. Meanwhile, the medium from T25 flask 
is replaced with 3 ml of OptiMEM medium and the transfection mixture was added to the 
cells. The cells in the flask were incubated with the transfection mixture for 4 hours. 
After 24 hours of transfection the cells were used for experimental purpose or collection 
for RNA or proteins. 
3.6  Expression of scFv62 TRAILLys agent  
The fusion proteins were expressed in stably transfected CHO K1 cells. The vector 
pSecTag2A has murine kappa leader sequences, which allow secretory protein 
expression. One week of selection was performed to achieve stably transfected cells. 
For protein expressions stably expressing monoclones were seeded at 80% confluency 
in T175 flasks. The medium was changed into serum-free medium Panserin C6000 
(PAN Biotech) for expression. This was incubated for 3-5 days and then the medium 
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supernatant was collected, concentrated with Centricon YM-100, sterile filtered and 
stored at 4°C. 
4.0  Lent-X Lentiviral Expression System (Clontech) 
Production of lentiviral particles. 
The packaging mix VSV-G envelope (cat no. 631259) and Lenti-X 293T cell line (cat no. 
632180) were used. The medium used for culturing Lenti-X 293T cell line was DMEM 
with high glucose (4.5g/L), 4 mM L-glutamine, and 3.7 g/L sodium bicarbonate (Sigma-
Aldrich cat no.D5796) 1 mM sodium pyruvate and 10% tetracycline-free fetal bovine 
serum. 
Polybrene (Hexadimethrine bromide; Sigma-Aldrich, Cat no. H9268) was needed for 
standard transfection to facilitate lentiviral gene transfer. It is a polycation that reduces 
the charge repulsion between the virus and cellular membrane.  The concentration that 
was optimized and used was 4 g/ml. RetroNectin reagent (Takara Bio, Inc., cat. No 
T100B) is a recombinant fragment fibronectin (CH-296) that was used to improve the 
lentiviral transduction efficiency.  It was coated onto the tissue culture plate to provide a 
substratum for the virus and cells to bind.  
The vial of Lenti-X 293T cell line was thawed rapidly on a 37 oC water bath, immediately 
after which the cells were transferred to a 15 ml centrifuge tube containing 1 ml pre-
warmed medium and gently mixed. Additional 4 ml of pre warmed medium was added 
to the tube.  Then it was centrifuged at 100 x g for 5 min, the supernatant was aspirated 
and the pellet of cells was re-suspended with complete medium and plated in culture 
flask. This was placed in a 37 oC humidified incubator with 5% CO2 for 24 hours. Once 
attached and confluent the cells were passaged and plated for transfection. For 
transfection purposes, 5 x 106 Lenti-X 293T cells/ 100 mm plate in 10 ml of complete 
medium were incubated at 37 oC, 5% CO2 overnight. Once the cells reach a confluency 
of 80% it was ready to be transfected.  
For transfection, two different tubes containing the plasmid DNA (Non-silencing-GIPZ 
lentiviral shRNAmir control vector or shRNA pGIPZ-hEag1(III) lentiviral particles vsv-g 
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envelope) were mixed with the viral packaging mix in one tube, and the Xfect polymer in 
another one were prepared as follows:  
 
 
Tube 1 Plasmid DNA Tube 2 Polymer 
557L Xfect reaction buffer 592,5L Xfect reaction buffer 
36L Lenti-X HTX Packaging Mix 7,5L Xfect Polymer 
7L Lenti-X Vector DNA (1 g/ml)    
600L Total volume 600L Total Volume 
(* X = Non-silencing-GIPZ lentiviral  shRNAmir control vector / shRNA pGIPZ-hEag1(III) lentiviral particles vsv-g envelope) 
The two tubes were vortexed (medium speed for 10 s) and mixed together. This mixture 
was incubated at room temperature for 10 min to permit nanoparticle complexes to 
form, and then added dropwise on to the cells. After gentle mixing, the plate was placed 
at 37 oC, 5% CO2 for 4 hours, and then the transfection mixture was replaced with fresh 
complete medium and placed back into the incubator for additional 48 hours, when viral 
titers are expected to be highest. The lentiviral supernatants were harvested and 
centrifuged at 500 xg to remove cellular debris. The viral stocks were verified with the 
help of Lenti-X GoStix, aliquoted and stored at -80 oC.  
Transducing target cells with the viral particles was performed in Retronectin-coated 6-
well plates, which were prepared by incubating the plate for 2 hours at room 
temperature with a 50g/ml solution of retronectin in PBS. Then, retronectin was 
removed and replaced with 2 ml of 2% Bovine serum albumin in PBS. This was allowed 
to stand at room temperature for 30 min and then was washed once with PBS.  
200L of the appropriate Lenti-X virus supernatant was added onto to the coated 
plates. The plate was then centrifuged at 1000 x g for 2 hours to help in binding the 
virus particles to the retronectin reagent, and then washed with PBS, making sure not to 
dry the plate. The target cells were then added at 1x106 cells/ well and incubated 
overnight.  
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For generating stably transfected cells, the medium was changed after 24 hours to 
medium containing Puromycin (0.5 g/ml). 
5.0  Characterization of stably transfected cell lines 
Stably transfected cell lines were generated for co-culture experiments involving cancer 
cell lines and stellate cells for the purpose of investigating their symbiotic relationship as 
per literature (Pandol et al. 2009).  
 
RLT-PSC cell lines were labelled with pBRY - nuclear mCherry - IRES – PURO as 
described above. Among the five PDAC cell lines we were successful in transducing 
Capan-1 cell lines shRNA pGIPZ-hEag1 vsvg envelope and Non-silencing pGIPZ 
lentiviral control vector as described in the materials and methods section.   
  
Figure 8 : Labeling of stellate cells and cancer cells for co-culture experiments. 
RLT-PSC cell’s nuclei labeled with pBRY-nuclear mCherry-IRES-PURO (left) and 
Capan-1 labeled with (shRNA pGIPZ-hEag1 vsvg envelope) and/or Capan-1 (Non-
silencing pGIPZ lentiviral control vector) (right). 












The knock down of Kv10.1 in Capan-1 cells was confirmed through real-time PCR. The 
down regulation we achieved was more than 90% compared to the wild-type cell line.  
 
 
We were only successful in over expression of Kv10.1 in PANC-1 and MIA PaCa-2 cell 
lines, which was confirmed through real-time PCR. We achieved a high stable over 
expression compared to the control. 
Figure 9:  Real-time PCR confirming knock down of Kv10.1 in Capan-1. RNA was 
isolated from Capan-1 GFP-shRNA-hEag-1 stably transfected cells and Capan-1 (Wild-
type).  5µg total RNA was used to synthesize cDNA and quantitative real-time PCR was 
performed with human transferrin receptor a reference gene.    
Figure 10: Real-time PCR confirming over expression of Kv10.1 in cancer cell 
lines. RNA was isolated from PANC-1, MIA PaCa-2 (wild-type, pCDNA3-Venus and 
pCDNA3-Venus-Eag-1) cells.  5µg total RNA was used to synthesize cDNA (as 
described in the materials and methods) and quantitative real-time PCR was 
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6.0  Protein extraction 
 
For detection of Cleaved Caspase-3, cells were collected by trypsinization and washed 
with PBS. After centrifugation, the cell pellet was re-suspended in non-denaturing lysis 
buffer and incubated for 30 minutes at room temperature. The lysis buffer contained 1% 
Triton X -100, 50 mM Tris-HCl, 300 mM NaCl, 5 mM EDTA and protease Inhibitor 
cocktail (Roche).  After incubation, the cell lysates were centrifuged at 11400 xg for 15 
min. The supernatant was collected into new 1.5 ml microcentrifuge tubes. 
For detection of Kv10.1, cells were collected by trypsinization and washed with PBS. 
After centrifugation, the cell pellet was re-suspended in 70 L lysis buffer (8M Urea, 
65mM DTT, 4% CHAPS, 1% NP-40) by constant vortexing. Thermal shock was 
performed by placing the suspension of cells in the lysis buffer first in liquid nitrogen 
until frozen, then at 37 oC degree (water bath) until thawed and vortexing for 30 s. This 
cycle was done 5 times. After which it was centrifuged at 2708 xg for 10 minutes (at 4 
°C). The supernatant was collected into a new 1.5ml micro centrifuge tube. 
 
6.1  Protein quantification with BCA Protein Assay  
 
Protein concentration was determined using Pierce BCA Protein Assay Kit. The protein 
lysates were diluted 1:5 with water and loaded in triplicates on a 96 well plate, together 
with triplicates of diluted BSA (bovine serum albumin) standard (0-2000 µg). Reagent B 
(4% cupric sulfate) was diluted 1/50 in Reagent A (sodium carbonate, sodium 
bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) and 
mixed thoroughly. 200 µL of this mixture was added to each sample in the 96-well plate 
and incubated for 30 min at 37 °C. The absorbance of the samples at 562 nm was 
measured using a Wallac VICTOR2 plate reader (Perkin Elmer). With these data we 
could draw a titration curve, which allowed us to estimate the protein amount relative to 
our samples. 
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6.2  SDS-PAGE 
 
The proteins were allowed to migrate depending on the mass to charge ratio during 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). NuPAGE 
reducing agent (Invitrogen) and NuPAGE LDS sample buffer (Invitrogen) pH 8.4 were 
added to the samples (to provide optimal conditions for reduction of disulfide bonds) (50 
μg of total protein for caspase-3, 200 μg for Kv10.1) in a 1:10 and 1:4 ratio to the final 
volume, respectively. The reducing agent removes any remaining tertiary and 
quaternary structures by reducing their disulfide bonds. These samples were heated at 
70 oC for 10 minutes.  
The denatured samples were then resolved in a 4-12% NuPAGE Novex Bis-Tris Mini 
Gels (Invitrogen) at 200 V using NuPAGE MOPS SDS Running Buffer (for caspase) or 
NuPAGE MES SDS Running Buffer (for Kv10.1), both with NuPAGE antioxidant. Along 
with the protein samples a ColorPlus prestain protein ladder (BioLabs) was run, to mark 





After the protein samples were separated by SDS-PAGE, they were transferred onto a 
nitrocellulose membrane (NC) (GE Healthcare, 0.2 μm for caspase, 0.45 µm for Kv10.1) 
using the electro-transfer protocol. For caspase 3, the transfer buffer used was 
composed of 10 mM NaHCO3, 3 mM Na2CO3, 0.01% SDS and 20% methanol, for 
Kv10.1 the transfer buffer used contained 8 M Urea, 25 mM Tris Base, 192mM Glycine 
and 20% methanol. The gel was removed from the cast and incubated for 30 minutes 
with the transfer buffer in order to equilibrate it before the transfer. 
For caspase immunoblotting, transfer was performed using a voltage-gradient protocol 
from 10 V and increased every 10 min by 10 V until 50 V, then maintained for 40 min. 
The NC membranes were subsequently rinsed with deionized water and incubated with 
Blot signal enhancer (Thermo Scientific) according to the manufacturer’s instructions.  
The membrane was incubated with Quentix enhancer Solution A for 2 minutes on a 
shaker and washed with deionized water 5 times, then incubated with Quentix enhancer 
solution B for 10 min, which was then washed with deionized water 5 times. The 
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membrane was then blocked with 0.1% Casein (Roche) in TBS-T (0,1% Tween 20) for 
1 hour. This was followed by incubating the membrane with the primary antibody of 
interest (Ref table 7) diluted in blocking buffer overnight at 4 °C on a shaker. The next 
day, the membrane was washed 5 times with deionized water and incubated with TBS-
T for 5 minutes, after which it was incubated with horseradish peroxidase (HRP)-
conjugated secondary antibody (Refer table 7) diluted in blocking buffer for 45 minutes.  
The membrane was washed 7 times with deionized water and incubated for 5 minutes 
in TBS-T.  
In the case of Kv10.1, the transfer was performed at 20 volts at 4° overnight on a 
magnetic stirrer. Next day, blocking was performed to prevent non-specific binding, 5% 
non-fat dry milk (Bio Rad) in PBS for 1 hour, followed by incubating the membrane with 
the primary antibody of interest (Ref table 7) diluted in blocking buffer on an orbital 
shaker for 2 hours. Next ECL peroxidase labeled anti rabbit antibody (Refer table 7) 
diluted in PBS for 1 hour.  The membrane was washed 3 times with PBS-T (10 
min/wash). 
Finally, the membrane was incubated for 5 minutes with chemiluminescent HRP 
substrate (Millipore) in order to initiate the chemiluminescence reaction catalyzed by the 
peroxidase conjugated to the secondary antibody. This reaction was detected with a 
ChemiDoc XRS system (Bio-Rad); the image acquisition was done using Quantity One 
1-D Analysis software v4.6.9 (Bio-Rad).  
7.0  Immunofluorescence: Immunohistochemistry 
 
Tumour tissue sections were first de-paraffined by washing in Xylene twice followed by 
ethanol series from 100%, 90%, 70% and distilled water. A water bath was heated to 
90° and antigen retrieval was performed in 10 mM citrate buffer (pH 6.0) for 30 minutes, 
after which the slides were allowed to cool down to room temperature for approximately 
an hour. The slides were then washed in TBS-T once for 5 minutes. Now to avoid non-
specific binding, blocking was performed with 10% BSA (Globulin free) in TBS-T for 1 
hour at room temperature.  The slides were then washed twice in TBS-T.  
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Primary antibody mAb62 in 1:100 dilution in blocking solution was prepared and the 
tissue sections were incubated overnight at 4 °C. Next day, the slides were washed in 
thrice in TBS-T (5 min/wash).  This was followed by 1 hour incubation with secondary 
antibody, goat anti-mouse IgG1 secondary antibody, Alexa Fluor 488 conjugate. The 
slides were then washed 1x in TBS-T (5 min/wash). For staining nuclei, DRAQ5 was 
used at 1:1000 dilution in blocking solution for 15 minutes. The slides were then washed 
1x in TBS-T (5 min/wash). Finally the sections were mounted with Prolong Gold antifade 
reagent with DAPI.  
After 24 hours, when the mounting medium was completely dry, the slides were 
visualized under LSM 510 Meta laser scanning confocal microscope (Zeiss). The ZEN 
(Zeiss) software was used for image acquisition and processing was done with the help 
of FIJI image anaylsis software.  
8.0  Live cell imaging  
 
The incuCyte Zoom is a live-cell imaging system that can be placed within an incubator. 
It is essentially a motorized microscope that can take images from cells growing in cell 
culture vessels of varying formats. The system used, equipped with three different 
objectives (4x, 10x and 20x) can produce phase contrast, green and red fluorescence 
images. Cell behavior and function can be monitored and quantified in real time. We 
employed the incuCyte system to perform proliferation assays by analyzing the increase 
in area occupied by cells (%) as the cells proliferate. Scratch assay was quantified by 
generating a scratch wound mask (width of the wound) and a confluence mask (cell 
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8.1  Caspase activity determination 
 
 
Apoptosis was monitored through activation of Caspase-3 (and -7), one of the main 
effector caspases involved in apoptosis in mammalian cells. This is achieved through 
cleavage of a caspase substrate that consists of a caspase-3/7 recognition motif 
(DEVD) coupled to a DNA intercalating dye. This non-fluorescent substrate crosses the 
cell membrane and is cleaved by activated caspases-3/7. This results in the release of 
the DNA dye, leading to green fluorescent staining of the DNA. 6000 cells/well were 
plated in a 96-well flat bottom plate. After 24 hours, once the cells were attached, the 
specific treatment was added (6 wells/treatment), along with 5 µM caspase-3/7 
substrate reagent. The plate was placed in the imaging system with both phase contrast 
and fluorescence green channels capturing images every hour. The images were used 
to quantify the green spots which represent stained DNA of an apoptotic cell. 
The treatments used were: 
1. scFv62TRAILLys   0,48g per ml 
2. Gemcitabine  25M  
3. Soluble TRAIL 0,48g per ml  
4. scFv62TRAILLys + Gemcitabine 
5. Soluble TRAIL + Gemcitabine  
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Pan Caspase Inhibitor Z-VAD-FMK was used along with the treatment at a 
concentration from 50M, 100M, 150M and 200M 









CellTox Green is a cell impermeant cyanine dye that stains DNA only when it can 
access the cell due to loss of membrane integrity as a result of the death of a cell. The 
dye is virtually non-fluorescent when not bound to DNA, and live cells do not produce 
any fluorescence. The fluorescent signal produced is proportional to the cytotoxicity. 
6000 cells per well were plated in a 96-well plates and allowed to attach for 24 h. Then, 
the specific treatment was added (6 wells/treatment) together with the cytotoxicity dye 
(1:1000). The plate was placed in the incuCyte and images were captured every hour in 
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8.3  Spheroid assay: 3D spheroid culture 
 
This protocol employs a round bottomed, hydrogel (hydrophilic and neutrally charged) 
coated 96-well plate, termed ultra-low attachment plate (ULA; corning 7007). The 
hydrogel inhibits specific and non-specific immobilization, thereby forcing the cells to be 
in suspension and enabling 3D spheroid formation. The IncuCyte automatically 




The cells (100 µL) were seeded at 5000 cells/well in combination with 2% matrigel. The 
plate was centrifuged at 163 x g for 10 minutes and then placed in the imaging system. 
Images were collected every hour. After 72 to 96 hours, firm spheroids of 400 to 500 m 
in size were formed. An equal amount (100 µL/well) of medium containing the 
treatments (2x concentrated) was then added to the wells. The treatment was 
replenished after 4 days by replacing 100 µL of the medium from the well to freshly 
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9.0  Annexin V-FITC/PI apoptosis Assay using Flow cytometry 
 
This assay is based on the detection of phosphatidylserine (PS) at the outer surface of 
the cell membrane and can be measured using flow cytometry. When a cell undergoes 
apoptosis, PS that is normally in the inner leaflet of the cell membrane flips to the outer 
surface of the membrane. This flip of PS  occurs in the early stages of apoptosis and 
remains this way for the rest of the dying process. Annexin V-FITC staining is used in 
conjugation with Propidium Iodide (PI) to differentiate between early apoptotic, late 
apoptotic and necrotic cells.  
In a 12 well plate 100,000 cells were plated per well.  When cells were attached after 24 
hours, medium was exchanged with new medium containing treatment in duplicates.  
The treatment (ref to caspase assay) proceeded for 12 h.  The cells were then washed 
with PBS, trypsinized, collected in tubes and centrifuged at 275 x g for 4 minutes. The 
cell pellet was washed with PB and re-suspended in 100 µL 1x annexin binding buffer 
(containing enough calcium to assist with the annexin V binding to PS on the cell 
surface), 4 µL annexin V-FITC and 4 µL propidium iodide (PI). This was incubated for 
20 minutes at room temperature in the dark.  After the incubation period, 400 µL of 1x 
annexin binding buffer was added and the samples were analyzed by flow cytometry. 
The FACSaria cytometer (BD sciences) was used to analyze the stained cells (Ex= 488 
nm and Em= 530 nm) using FL1 channel for detecting Annexin V FITC staining and the 
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The annexin V reagent from Essen Bioscience is a cyanine–based fluorescent dye, 
bases on the same principle as the flow cytometric assay described above. The reagent 
is non-fluorescent in solution, but gives rise to a bright and photo stable fluorescent 
signal when bound to PS. 6000 cells per well were plated in a 96-well plate, and after 24 
hr the specific agents were added together with annexin V reagent (1:200 dilution). The 
wells were imaged every hour using the IncuCyte system. The fluorescent intensity is 
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11.0  TRAIL and IL-8 concentrations were determined by Enzyme-
linked Immunosorbent Assay (ELISA).  
 
The Quantikine Human TRAIL/TNFSF10 Immunoassay was used to measure human 
TRAIL in cell culture supernatants. We employed a microplate pre-coated with 
monoclonal antibody specific for human TRAIL. The standards and samples to be 
measured were pipetted into the wells, sealed and incubated for 2 hours in an orbital 
shaker. Unbound material was washed out with a Wash buffer (four times with buffered 
surfactant), and an enzyme-linked polyclonal antibody specific for human TRAIL was 
added to the wells. The plates were again sealed and incubated for further 2 hours in an 
orbital shaker. The wells were washed four times to remove unbound antibody-enzyme 
reagent, and substrate solution (a mixture of hydrogen peroxide and 
tetramethylbenzidine in equal volumes) was added to the wells and incubated at room 
temperature in the dark for 30 min.  
The reaction was stopped using 2 N sulfuric acid, and the color developed was 
measured in a Wallac Victor 2 photometer at 570 nm. The unknown concentrations 
were interpolated from a log-log standard curve generated using 1000, 500, 250, 125, 
62.5, 31.2, 15.6, and 0 pg/ml human TRAIL).  
IL-8 levels were measured in a similar manner, using a luminescent substrate. Culture 
supernatants were diluted (1:5).  Samples were pipetted in the wells of a plate 
precoated with an anti-human IL-8 capture antibody and incubated for 1 hour at room 
temperature. After washing thrice with the wash buffer, 50L of biotinylated antibody 
reagent binding to a second site on the IL-8 protein was added, and the plate was 
sealed and incubated for 30 min at room temperature. Excess detecting antibody was 
removed with three washes and streptavidin-HRP reagent was added and incubated for 
30 min at room temperature. The plate was washed thrice and pat dried.  50 L 
Supersignal working solution was added which was prepared with one part stable 
peroxide to one part of luminol enhancer.  
The plate was read in luminometer within 15 min of addition. The luminescence was 
read for 1 s per well and is proportional to the amount of human IL-8 in standard or 
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sample. The average relative light (RLU) obtained from each standard (500, 50, 5, 0.5 
and 0 pg/ml IL8) was used to interpolate the concentration in the unknown samples.  
12.0  Cell Migration Assay  
 
Migration was determined by trans-well assay, by determining the amount of cells that 
move between two chambers through a membrane with 8 µm pores, following a nutrient 
gradient. Prior to performing this assay the cells were starved overnight. The next day 
the cells were harvested and counted and a cell suspension of 5x105 cells/ml in serum 
free medium was prepared. The 24-well migration plate was allowed to warm up at 
room temperature for 10 minutes under sterile conditions. 500 µL of medium containing 
10% fetal bovine serum was added to the lower well of the migration plate and 300 µL 
of the cell suspension solution was added into each insert. The plate was incubated for 
24 hours.  
Next day, the medium from the inserts was carefully aspirated, and the inner part was 
gently scraped with a wet, flattened cotton-tipped swab, thereby removing the non-
migrating cells without puncturing the polycarbonate membrane. Then the inserts were 
transferred to a clean well containing 400 µL of Cell Stain Solution (crystal violet) and 
incubated for 10 minutes at room temperature. After staining, the inserts were gently 
washed several times in a beaker of water to remove excess staining. Each insert was 
transferred to a well containing 200 µL of extraction solution per well and incubated for 
10 minutes on an orbital shaker. From the cell suspension 100 µL was pipetted into a 
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13.0  Animal experiments 
 
The animal study was conducted in accordance to German law and approval by the 
local ethical LAVES committee (no. 33.19-42502-04-15/1845). A total of 32 mice which 
were 8 week-old female CB17/Icr-Prkdcscid/IcrCr mice (Charles River) were used in this 
study. They were housed in individually ventilated cages (two mice per cage), with free 
access to food (autoclaved pellets) and water.  
Implantation: 
The medium from the T175 flask was aspirated and washed once with PBS. 5 ml of 
trypsin was added onto the cells in the flask and incubated for 4 min until the cells 
detached. Cells were harvested and counted as described earlier and 5x106 cells/200 
L of PBS of Capan-1 was injected with 1 ml syringe (BD Plastipak Ref no. 300013) and 
Needle (BD Microlance 3 27Gx ¾ ‘’ Nr 20 Ref no 302200) subcutaneously into the flank 
of the animal. The mice were monitored once every two days. One week after 
implantation the first tumour volume measurement was done, and thereafter by the 
same person throughout the experiment. The length and width of tumour were 
measured with which the tumour volume was calculated.  
 
Tumour volume (mm3) = Length (mm)*width (mm)*width (mm)*0.5 
 
Treatment: We had four groups (8 mice/group);  
1. Control  
2. scFv62TRAILLys 
3. Gemcitabine and  
4. Combination.  




First dose of treatment started 2 weeks after the implantation, intra-peritoneal with 80 
mg/kg of Gemcitabine (200 L) followed by the scFv62TRAILLys (200 L) next two days 
as shown in the diagram above. This treatment cycle lasted for two weeks and 
simultaneously the tumour volume was monitored. 
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1. Kv10.1 is expressed in PDAC cell lines 
 
1.1 Expression of Kv10.1 in PDAC cell lines at the transcript level 
 
The voltage-gated potassium channel Kv10.1 is normally expressed in the CNS of 
humans and rodents (Martin et al. 2008). Recently, it was demonstrated that all cells 
express Kv10.1 in a cell cycle phase-specific manner, in a short time window during 
G2/M. Channel expression contributes towards progression through G2/M. This could 
explain the aberrant expression of Kv10.1 observed in tumours of diverse origins 
(Urrego et al. 2016). To determine if –and if so, which one- of the studied PDAC cell 
lines belong to the Kv10.1-positive group, we isolated total RNA from each of the cell 
lines and reverse transcribed it to obtain cDNA using oligo-dT as primer. On this 
material, we performed nested PCR as described in materials and methods (Ramos 
Gomes et al. 2015), which also allows distinguishing between alternatively spliced 
variants.  
 
Figure 11: Analysis of the expression of Kv10.1. RNA was isolated from the five 
PDAC, SH-SY5Y and RLT-PCS cell lines.  cDNA was synthesized from 5 µg of total RNA 
as described in Materials and Methods and PCR was performed on the samples.  a. 
Nested PCR detected expression of Kv10.1 in the cell lines. b. Real-time PCR confirmed 




Capan-1, PANC-1, AsPC-1, and MIA PaCa-2 cDNA gave rise to bands of the same size 
as to those from the positive control (SH-SY5Y neuroblastoma cells (Ramos Gomes et 
al. 2015)  (Fig. 11). Only AsPC-1 showed a band compatible with known Kv10.1 splice 
variants. 
Quantitative real-time PCR (RT-PCR) using TaqMan probes (see Methods) confirmed 
the expression of Kv10.1 in those cell lines (Fig. 11). Expression levels were normalized 
to the reference housekeeping gene transferrin receptor. The positive control SH-SY5Y 
had the highest expression levels, while MIA PaCa-2 had the lowest. Immortalized 
human pancreatic stellate cells (RLT-PSC) were tested in the same experiments, and 
showed also low expression of Kv10.1  
The intensities of the bands from nested PCR were not parallel to RT-PCR values. 
Besides the intrinsic qualitative nature of conventional PCR, could reflect differences in 
cell cycle distribution between experiments. From these experiments, we conclude that 
all cell lines, and also PSCs, express Kv10.1 at modest levels,  
 









Figure 12: Protein expression of Kv10.1.  Lysates were extracted from Capan-1, 
BxPC-3, RLT-PSC cell lines and HEK-A cell line (positive control).  100 µg total 
protein was loaded and immunoblot was performed as described in the Materials and 





To confirm expression of Kv10.1 also at the protein level, we collected extracts of the 
cell lines relevant for further experiments (see below), both PDAC and stellate cells. A 
polyclonal antibody against the C-terminus of the channel detected ~110 and ~130kDa 
bands, compatible with Kv10.1 and similar to those present in HEK-A cells (a stably 
transfected HEK-derived clone). The highest expression level was detected in Capan-1, 





1.3  Expression of Kv10.1 in tumour tissues 
 
 
Expression of Kv10.1 in cultured cells does not necessarily mean that the protein is 
expressed in the tumours. To confirm expression in vivo, we stained slices from 
tumours obtained through orthotopic implantation of Capan-1 and BxPC-3 cells. 
Slices cut from paraffin blocks from tumours were stained using the monoclonal anti-
Kv10.1 mAb62 (Hemmerlein et al, 2006) and a secondary antibody labeled with Alexa 
Fluor 488. DRAQ5 was used for counterstaining the nuclei. The slices were imaged by 
confocal microscopy. The green fluorescence indicating the presence of Kv10.1 was not 
homogeneously distributed in the tissue, rather there were restricted areas of positivity 
(also in haematoxylin-eosin staining; not shown). Within those positive areas (Fig 13), 
the staining was more intense in Capan-1 tumours. 
 
 
Figure 13: Expression of Kv10.1 in tumour tissue. Confocal image of 
immunofluorescence staining of Kv10.1 in orthotropic tumour model of Capan-1 (left) 




2. Functional analysis of Kv10.1 in PDAC cell lines 
Earlier studies investigating the functional role of Kv10.1 have demonstrated that in vitro 
knock down in several cell lines leads to a reduction in the rate of proliferation and in 
migration (Ouadid-Ahidouch et al. 2016). We wanted to investigate if the functional role 









To do this, we first tested the effects of short-term RNAi-mediated knockdown of 
Kv10.1. Transient knockdown was carried out by already characterized siRNA (Weber 
et al. 2006) in all five PDAC cell lines, and confirmed by real-time PCR. We then 
determined proliferation by live cell imaging using the IncuCyte system. Using phase 
contrast images and with the help of IncuCyte zoom software, we determined the area 
of the culture surface covered by cells (confluence) and used it as a measure of 
proliferation.  
Figure 14: Effect of knock down of Kv10.1 on proliferation.  The effect of the knock 
down of Kv10.1 was cell line specific. Confluence mask indicated an increase in 




The effect of transient knock-down of Kv10.1 was cell-type dependent. While in Capan-
1 and PANC-1 cells we observed a modest but a significant increase in the rate of 
proliferation, against the pattern described in the literature with other cell lines, in MIA 
PaCa-2 cells there was a significant decrease in proliferation. In AsPC-1 and BxPC-3 no 
difference was observed. 
  
We also studied migration, using trans-well assays with the five PDAC cell lines. 
Knockdown of Kv10.1 had a significant effect only in BxPC-3 cells, whose migration was 
reduced by approximately 50% upon knockdown compared to the control cells (Fig 15). 
There was no significant effect in any of the other cell lines tested. 
Figure 15: Effect of knock down of Kv10.1 on migration. No significant effect of 
knock down of Kv10.1 in four of the PDAC cells, however there is reduction in the rate 




 We then attempted to generate long-term knockdown PDAC cells lines for Kv10.1 via a 
shRNA-mediated strategy. However, we were only successful in generating stable 












The rate of proliferation was significantly reduced in Kv10.1 knock down cells compared 
to the controls Figure 16, in contrast to the results obtained with transient knockdown. 
However, in trans-well assays, we observed no significant difference in the rate of 
migration in knockdown cells compared to the controls.  
Therefore, we conclude that knock down of Kv10.1 in vitro leads to a decrease in the 
rate of proliferation of –at least– Capan-1 and MIA PaCa-2 cells, but does not affect 
migration of any of the cell lines.   
 
Figure 16: Reduction of rate of proliferation in Kv10.1 knock-out Capan-1 cells.  
Confluence mask indicated a decrease in the proliferation in Kv10.1 knock down 
Capan-1 cells compared to the control.   






































We also performed overexpression experiments, using a vector that contains Kv10.1 
fused to the yellow fluorescent protein mVenus under the control of the CMV promoter.  
All five PDAC cell lines were transfected with pCDNA3-Venus and pCDNA3-Venus-
Kv10.1, but we could successfully generate stably transfected cell lines of only PANC-1 
and MIA PaCa-2 cells. 
 
 
Figure 17: The rate of migration of Capan-1 cells was not affected by stable 
Kv10.1 knockdown.  
Figure 18: Kv10.1 over expressing cells show a cell line specific effect.  
Confluence mask indicated an increase in rate of proliferation in Panc-1 cells over 





In live cell imaging experiments, a significant increase in the rate of proliferation in 
Panc-1 (pCDNA3-Venus-Eag-1) compared to PANC-1 (pCDNA3-Venus) was observed, 
while in MIA PaCa-2 we detected no effect (Fig 18). 
 
We further went on to investigate the effect on migration using the trans-well assay as 
described before. We observed there was no significant difference in the rate of 
migration between the wild-type, pCDNA3-Venus and pCDNA3-Venus-Eag-1 in both 
PANC-1 and MIA PaCa-2 Fig 19. 
 
3.  Effects of scFv62TRAILLys and Gemcitabine on PDAC cell lines in 
single 2D culture. 
The results described up to now showed a limited relevance of Kv10.1 expression in the 
proliferation of PDAC cell lines, and would argue against the use of Kv10.1 
blockers/modulators in therapy. Nevertheless, Kv10.1, due to its enrichment in tumour 
tissue, can still be used as a label to target other agents to the tumour site. Over the last 
15 years several therapies involving antibodies have been established as successful 
Figure 19: No significant effect of Kv10.1 on the rate of migration.  Both cells lines 




strategies for treating patients with both haematological and solid tumours. We set out 
to investigate the potential of Kv10.1 as a target in PDAC cell lines. We achieved this 
with an in-house constructed bi-functional antibody which has a Kv10.1-specific 
(scFv62) antibody fused to TRAILLys (optimized TRAIL mutant).  
For our study we have used Capan-1, which is positive for Kv10.1 and also known to be 
resistant to TRAIL-induced apoptosis, and the BxPC-3 cell line, which is known to be 
sensitive to TRAIL-induced apoptosis (Wang et al. 2007, Wicker et al. 2010).   
3.1  Effect of scFv62TRAILLys on PDAC cell viability 
This assay was performed to test the concentration and the degree of cytotoxicity of 
scFv62TRAILLys (0.48 g/mL) alone and in combination with Gemcitabine (25 M) on 
the PDAC cells. These experiments detect cell death, irrespective of the mechanism of 
cytotoxicity. 
Capan-1 cells were treated with scFv62TRAILLys alone or in combination with 
Gemcitabine along with the CellTox dye (1:2000 dilution) as described in the Methods 
section. Gemcitabine (25 µM) or sTRAIL (0.48 µg/mL) alone induced virtually no 






Figure 21: Cytotoxicity induced in BxPC-3 cells. High level of toxicity observed in 
these cells that were treated with both combination therapy 
Figure 20: Cytotoxicity induced in Capan-1 cells. High level of toxicity observed in 





In contrast, both agents combined produced an increase in green fluorescent (dead) 
cells after approximately 6 hours of treatment. scFv62TAILLys (0.48 g/mL) alone 
already induced cytotoxicity from the first hours. Combination of Gemcitabine and 
scFv62TRAILLys induced the death of a significantly larger fraction of cells, representing 
approximately 3.4 fold the extent of cytotoxicity induced by Gemcitabine alone and 1.4 
fold compared to scFv62TAILLys alone.  
When the equivalent experiment was performed on BxPC-3 cells Fig. 21, Gemcitabine 
alone again failed to induce cell death. In contrast, sTRAIL, both alone or in combination 
induced a clear increase in the fraction of non-viable cells. This was expected, because 
BxPC-3 cells are known to be sensitive to TRAIL (Wang et al. 2007). scFv62TRAILLys 
again induced the strongest effect, but in this case there was no difference between the 
construct alone or in combination with Gemcitabine. Still, the treatment with the 
construct in combination with Gemcitabine showed an 8.6 fold increase in cytotoxicity 











3.2  Cell death induced by combination treatment is largely due to 
apoptosis  
 
To investigate the mechanism of cytotoxicity induced by the different treatments, we 
measured activation of Caspase-3/7 as indicator of apoptotic cell death.  During 
apoptosis, caspase-3 is one of the main effector caspases that are activated. The assay 
we used consists on the addition of a cell-permeant caspase-3/7 substrate to the 
medium. When cleaved, the reagent releases a DNA intercalating dye. The activated 
caspase-3/7 results in green fluorescent nuclei.  
 
The live-cell imaging was performed in the IncuCyte Zoom. The zoom software was 
used to generate a process definition that created a mask for the green fluorescent 
staining and thereby quantified the number of apoptotic (caspase-positive) cells.  
In Capan-1 cells, no or very little apoptosis was detected over a 24 h period in the 
control, or when 25 µM Gemcitabine, sTRAIL (0.48 µg/mL) or the scFv62TRAILLys (0.48 
µg/mL) construct alone were added to the medium Fig. 22. There was a significant 
Figure 22: Increase in Caspase-3/7 activity observed in Capan-1 cells when 




increase in apoptotic cells on treatment with scFv62TRAILLys in combination with 
Gemcitabine compared to Gemcitabine alone (5.2 fold). There was also a significant 
increase in apoptosis in cells treated with scFv62TRAILLys in combination with 
Gemcitabine compared to scFv62TRAILLys. 
  
In BxPC3, caspase activity was low in the control over a 30 h period Fig. 23. We did not 
observe a consistent increase in caspase activity in the presence of sTRAIL alone, 
although as mentioned previously, BxPC-3 cell line is reportedly sensitive to TRAIL-
induced apoptosis (Wang et al. 2007). In contrast, scFv62TRAILLys alone induced 
apoptosis in a relevant fraction of cells. scFv62TRAILLys in combination with 
Gemcitabine showed an additive effect, and the induction of apoptosis was significantly 
larger than with Gemcitabine or scFv62TRAILLys alone. The treatment with 
scFv62TRAILLys in combination with Gemcitabine had a significant  2.7 fold increase in 
caspase activity compared to Gemcitabine alone. Interestingly, we also observed that 
addition of Gemcitabine to sTRAIL slowed down the activation of caspase Fig. 23. 
Despite the absence of caspase activation in cells treated with sTRAIL alone, the 
Figure 23: High Caspase-3/7 activity induced in BxPC-3 cells when treated with 




viability of cells treated with sTRAIL alone and in combination with Gemcitabine was 
reduced (see Fig. 21).  
To confirm that the increase of fluorescence that we used as indicator of apoptosis is 
indeed due to caspase activation, we performed similar experiments to those described 
above in the presence of the general caspase inhibitor Z-VAD-FMK, which binds to the 
active site of the activated proteases thereby inhibiting apoptosis (Zhang et al. 2015).  
 
 
Capan-1 cells were treated with scFv62TRAILLys (0.48 g/ml) and Gemcitabine (25 M) 
along with caspase-3/7 substrate, with or without Z-VAD-FMK (200 M). Live-cell 
imaging revealed a significant reduction of the caspase reporter signal in the cells in the 
presence of caspase inhibitor. Therefore, the green fluorescent signal is likely due to 
activation of caspase. 
As a more direct test for caspase activation, we performed western blot detection of 
cleaved caspase-3 in cells treated as in the previous experiments. This test 
Figure 24: Fluorescence is significantly reduced in the presence of Caspase-3/7 
inhibitors. When treated with combination therapy in the presence of Z-VAD-FMK 




distinguishes additionally between Caspase-3 and Caspase-7 (through both antibody 
specificity and band size).  
 
 
Capan-1 and BxPC-3 cells were treated with scFv62TRAILLys alone or in combination 
with Gemcitabine for 12 hours. Cells were then harvested and lysed for western blotting 
using anti-cleaved caspase-3 antibody as described in the Methods section. Capan-1 
cells treated with scFv62TRAILLys and Gemcitabine, or with TRAIL and Gemcitabine, 
showed intense bands corresponding to active (cleaved) caspase (17kDa and 19kDa) 
(Chandler et al. 1998). The ~26kDa band could correspond to an additional cleavage 
product previously reported by others (Nakajima et al. 2011), and not to Pro-caspase-3, 
which is expected to be significantly larger. These experiments confirmed the activation 
of caspase-3 when both Gemcitabine and TRAIL were present.  
BxPC-3 cells treated with scFv62TAILLys or scFv62TAILLys in combination with 
Gemcitabine showed strong bands corresponding to cleaved caspase-3, while 
Gemcitabine and sTRAIL produced only very faint bands.  
Figure 25: Immunoblot analysis of cleaved Caspase-3. 50µg total protein was 
loaded and Immunoblot was performed as described in the Materials and Methods 
section. Protein expression of cleaved caspase-3 (17kDa, 19kDa and ~26kDa) was 




These results correlate well with to the caspase-3/7 activity observed in live cell imaging 
lines in Figure.  21 and 23. 
 
 
One of the first events when a cell undergoes apoptosis is the loss of asymmetry of the 
plasma membrane; thus, phosphatidylserine (PS), a phospholipid normally present in 
the inner leaflet of the cell membrane, flips to the outer surface and is exposed to the 
medium and accessible to Annexin V binding. Flow cytometry experiments were 
performed using fluorescently labeled Annexin V to stain PS together with propidium 
iodide (PI), which enters only dead cells because of the incompetence of the 
membrane. Early apoptotic cells will be annexin V positive and PI negative, while late 
apoptotic cells are double positive. Necrotic cells are only positive for PI.  
Figure 26: Increase apoptotic cells determined by flow cytometry. On treatment 
with scFv62TRAILLys in combination with Gemcitabine led to a significant increase in 
apoptosis compared to Gemcitabine alone in both Capan-1 (left) and BxPC-3 (right) 




Capan-1 and BxPC-3 cells were treated with scFv62TRAILLys in combination with 
Gemcitabine for 15 hours. Annexin V/PI staining was performed as described in the 
Methods section and analysed by FACS. In Capan-1 cells, the amount of viable cells 
decreased substantially with combination treatment with scFv62TRAILLys and 
Gemcitabine as compared to the controls; this was accompanied by an increase in early 
and late apoptotic cells. Both agents used alone induced less reduction in viability. 
BxPC-3 cells are more sensitive to scFv62TRAILLys, and the combination also induced a 
clear significant increase in apoptotic cells (Fig. 21 & 23).  
Annexin V assay was also performed on Capan-1 and BxPC-3 cells during treatment 
and live cell imaging in the IncuCyte as described in the Methods section.  
In Capan-1 cells treated with scFv62TRAILLys in combination with Gemcitabine, there 
was a significant increase in Annexin V binding when compared to Gemcitabine. The 
difference was also significant between scFv62TRAILLys alone and in combination with 
Gemcitabine (Fig. 27).  
Figure 27: Annexin V binding in Capan-1 measured in live cell imaging. Treatment 





The same experiment was performed on BxPC-3 cell line. In contrast to Capan-1, both 
scFv62TRAILLys alone and in combination with Gemcitabine produced a significant 
increase in apoptosis when compared to Gemcitabine alone (Fig. 28). There increase in 
apoptotic cells in scFv62TRAILLys in combination with Gemcitabine when compared to 
scFv62TRAILLys alone was also significant. Therefore, the outcome of this experiment 
confirms the results observed in flow cytometry (Fig. 26). 
3.3 TRAIL is required to induce apoptosis under combination 
treatment 
To elucidate if the caspase activation detected upon combination treatment with 
Gemcitabine and scFv62TRAILLys is actually due to TRAIL activation, we performed 
experiments were the TRAIL moiety of the construct had been omitted. We used 
scFv62-Cys, a construct where the TRAIL sequence is absent and substituted by a 
single cysteine residue to allow labeling. 
Figure 28: Annexin V binding in BxPC-3 in live cell imaging. Treatment with 





scFv62-Cys induced a marginal increase in apoptosis when added alone to the culture 
medium; apoptosis was slightly increased when scFv62-Cys was combined with 
Gemcitabine. In any case, either alone or in combination, scFv62-Cys gave rise to 
significantly less apoptosis than what was induced by scFv62TRAILLys. We therefore 
conclude that at least a major fraction of the apoptosis induced by scFv62TRAILLys 
requires the presence of TRAIL. Since the scFv62-Cys antibody was produced under 
the same conditions as scFv62TRAILLys, these experiments also ruled out the presence 
in the preparation of a contaminating apoptosis-inducing factor other than the construct 
itself.  
3.4  One-hour exposure to scFv62TRAILLys is sufficient to trigger 
apoptosis 
To discern the kinetics of apoptosis during our treatment we performed a caspase 
assay wherein cells plated were pre-treated for 3 hours with Gemcitabine along with 
caspase-3/7 substrate. Subsequently, scFv62TRAILLys was added and incubated for 
either 1 hour, 3 hours or maintained for entire period of the experiment as described in 
the Methods section. It should be noted that Gemcitabine was present throughout the 




experiment and that it was the scFv62TRAILLys that was removed after the incubation 
time. 
 
As shown in Figure 30, 1 hour incubation was enough to trigger induction of apoptosis. 
It can also be observed that 3 hours of incubation produced the same level of apoptosis 
as when scFv62TRAILLys was maintained throughout the experiment. 
 
4.  Effects of scFv62TRAILLys and Gemcitabine on PDAC cell lines 
co-cultured with stellate cells. 
PDAC is unique to other solid tumours because of the presence of an intense stromal 
reaction, to which pancreatic stellate cells are major contributors. This stromal reaction 
and stellate cells play a role in chemo-resistance (Pandol et al. 2009).  We wanted to 
test the effect of our treatment strategies on human stellate cells. For this purpose we 
used pancreatic stellate cells immortalized with telomerase and SV40 virus large T 
antigen (RLT-PSC). 
Figure 30: 1-hour incubation with scFv62TRAILLys is sufficient to trigger 
apoptosis. High Caspase-3/7 activity in Capan-1 cells when treated with 




4.1  sTRAIL, scFv62-TRAILLys, and Gemcitabine trigger minimal 
apoptosis in RLT-PSC cells  
 
RLT-PSC cells were treated with scFv62TRAILLys alone and in combination with 
Gemcitabine along with the caspase-3/7 substrate (5M). Figure 31 represents the 
caspase activity on the stellate cells up to 30 hours. Interestingly, we observed that 
there was no significant caspase activity induction with any of the treatment strategies 
on the stellate cells.  






The marginal effects on caspase-3 activation of the treatments on RLT-PSC cells were 
confirmed by western blot. Cells were treated with scFv62TRAILLys alone or in 
combination with Gemcitabine for 12 hours, and then harvested and lysed for western 
blotting using anti-caspase-3 antibody as described in the Methods section. Cells 
treated with scFv62TRAILLys and Gemcitabine, and scFv62TRAILLys showed faint bands 
corresponding to active (cleaved) caspase-3 (17kDa and 19kDa) (Chandler et al. 1998). 
The abundance of cleaved fragments was not comparable to that seen in tumour cells 
(see Fig. 25). 
Figure 32: Immunoblot analysis of Cleaved Caspase-3. 30µg total protein was 
loaded and Immunoblot was performed as described in the Materials and Methods 
section. Protein expression of cleaved caspase-3 (17kDa, 19kDa and ~26kDa) was 




We went on to look into the rate of proliferation during treatment on RLT-PSC. For this 
purpose with the help of IncuCyte zoom, a processing definition for creating a 
confluence mask was generated. During the 30 hours the cells grew only slightly, but 
Gemcitabine in any combination abolished this proliferation.  
4.2  RLT-PSC sensitize PDAC cells towards combination treatment 
We then performed co-culture experiments of PDAC and PSCs, to investigate if the 
stellate cells would in fact make cancer cells resistant. To differentiate the two cell 
types, PSCs were transfected with nuclear mCherry 
 
Figure 33: Gemcitabine inhibits proliferation of RLT-PSC cells.  Confluence of RLT-
PSC up to 30 hours showed no difference between the different treatments; cells in the 




The mixed culture was treated with scFv62TRAILLys and Gemcitabine, alone or in 
combination, and caspase-3/7 activity was monitored over time. Under these conditions, 
control cells and single treatments behaved qualitatively similar to single cultures of 
Capan-1 cells. However, the combination of scFv62TRAILLys and Gemcitabine 
increased the number of Capan-1 apoptotic cells clearly more than when tumour cells 
were cultured alone (1.6 fold). Therefore, the stellate cells had a sensitizing effect on 
cancer cells.  
 
  
Figure 34 Caspase-3/7 activity doubled in Capan-1 cells when co-cultured with 




The increase in the abundance of apoptotic cells upon treatment with scFv62TRAILLys in 
combination with Gemcitabine was due to tumour cells undergoing apoptosis, and not 
stellate cells. This was confirmed by monitoring the amount of red nuclei (PSCs) at the 
same time point, which showed that the presence of Gemcitabine arrested the growth of 
PSCs, and the number of red nuclei count remained constant. In the case of stellate 
cells, there was no significant difference between treatment with Gemcitabine alone or 
in combination.   
 
  
Figure 35: Stellate cells (RLT-PSC) tolerated the different treatments. No 
dramatic effect was detected with the treatment with scFv62TRAILLys alone or in 






Similarly, BxPC-3 and RLT-PSC cells (nucleus labelled with m-Cherry) were co-cultured 
and treated with scFv62TRAILLys alone and in combination with Gemcitabine.  As with 
Capan-1, in BxPC-3 cells that were co-cultured with stellate cells and then treated, the 
combination therapy once again had the highest caspase activity, and the effect was 
more intense than in monocultures of BxPC-3 cells.  In case of these cells there was no 
significant difference in caspase-3/7 activity when compared to the non-co-cultured 
cells. 
  
Figure 36: Caspase-3/7 activity in BxPC-3 co-cultured with stellate cells. The 
increase in apoptosis when compared to cultures without stellate cells on treatment with 





The effect of the treatment on the RLT-PSC cells was similar to what was observed in 
the previous experiment (Fig. 35) involving the co-culture experiment with Capan-1. 
Once again the amount of red nuclei of the PSCs in the same cultures remained 
constant indicating that Gemcitabine had the same effect in terms of arresting the 
growth of PSCs (Fig. 37). 
  
Figure 37: RLT-PSC in co-culture with BxPC-3 tolerated the different treatments. 





5. scFv62TRAILLys does not increase expression of IL-8 
 
As mentioned in the Introduction, it is known that under some circumstances TRAIL can 
induce an increase in proliferation/invasion in tumour cells, and that this effect is 
mediated through an inflammatory signaling pathway; when this happens, TRAIL-
treated cells produce the pro-inflammatory cytokine IL-8 (Zhou et al. 2008, Zhou et al. 
2013). To evaluate if this happens in our experimental models, we measured the levels 
of IL-8 in our cells after treatment with scFv62TRAILLys.  
 
Figure 38: IL-8 expression after treatment. Capan-1 cells were treated with 
scFv62TRAILLys alone and in combination with Gemcitabine. Both the supernatant 
and cells were collected for total protein and IL-8 detection via ELISA. IL-8 expression 





Capan-1 cells were treated with scFv62TRAILLys alone or in combination with 
Gemcitabine for 15 hours. Cells were then harvested and lysed for quantification of total 
protein. The supernatant was also collected for detection of expression of IL-8. As 
shown in Figure 38, Gemcitabine induced an increase in IL-8 expression. Treatment 
with scFv62TRAILLys alone did not induce IL-8 expression when compared to control 
treated cells, and it did not increase significantly the levels of IL-8 when combined with 
Gemcitabine in comparison to Gemcitabine alone (Fig. 38) 
6. Effects of scFv62-TRAILLys on PDAC cells in 3D cultures 
 
Traditional 2D cell culture techniques have a limited predictive value; for example, they 
do not model the difficulty in access for the drugs to tumour cells that is available in a 
3D structure. To address this, we tested our treatment strategy on a 3D cell culture 
model before progressing to in vivo tests.  
 
To generate a model closer to the in vivo situation, we attempted experiments in 3D 
cultures of tumour spheroids. Capan-1 cells were cultured in 2% matrigel in low 
Figure 39: Capan-1 shows dependency on stellate cells to form compact 
spheroids. (a) Capan-1 “spheroid” alone; (b) shows the same spheroid after the 
addition of fresh medium. (c) shows Capan-1 plus RLT-PSC (red fluorescent) 




attachment plates and followed through live cell imaging as described in the Methods 
section. The presence of matrigel and the use of ultra-low attachment plates force the 
cells to attach to each other and for a so-called tumour spheroid. Figure 39 represents a 
spheroid formed by Capan-1 after 7 days; morphologically, the group of cells resembled 
a loose sphere. There were apparently few cell-to-cell attachments, because upon 
manipulation, for example addition of fresh medium, the cells completely disaggregated 
(Fig. 39). In contrast, when Capan-1 and RLT-PSC cells were cultured together, stellate 
cells formed a shell that encapsulated the tumour cells, and formed tight compact 
spheroids in as short as 3 days. Addition of fresh medium did not disturb the spheroid 
(Fig. 39). 
 
Thus, spheroids were formed with Capan-1 and RLT-PSC in 3D spheroids, and treated 
when spheroids reached 400-500 µm in diameter. Under such conditions, Gemcitabine 
alone induced a marked caspase-3/7 activity. It apparently killed a majority of the cells 
within the first 60 hours, and caspase signal decreased thereafter (Fig. 40). We also 
saw an increase in caspase-3/7 activity on treatment with scFv62TRAILLys alone and in 
Figure 40: Increase in caspase activity in Capan-1 when co-cultured with RLT-
PSC. In 3D culture model system there is an increase in caspase activity in Capan-1 




combination with Gemcitabine.  In contrast to the gemcitabine treatment alone, the 
caspase activity persisted and increased even after 60 hours. Using IncuCyte zoom 
software, we were able to quantify only an approximate number of apoptotic cells, 
because we could not accurately quantify the signal coming from deep areas of the 
spheroid. 
To overcome this difficulty, we used modified Capan-1 cells that express constitutively 
GFP, in combination with red fluorescence-labeled stellate cells, and counted red and 
green particles in the spheroid. In these experiments, we observed a decrease in green 
(Capan-1) cells both upon treatment with Gemcitabine and in combination 
scFv62TRAILLys (Fig. 41) 
 
  
Figure 41: Decrease in growth rate of Capan-1 GFP-shRNA when co-cultured with 
RLT-PSC mCherry in 3D culture model. Proliferation of Capan-1 cells upon treatment 




In contrast, all treatments induced an arrest of red fluorescent cells (stellate cells; Fig. 
42) in co-culture. This was again surprising, because when cultured alone RLT-PSC cell 
spheroids were not affected by scFv62TRAILLys (Fig. 43) 
When RTL-PSC cells were grown in spheroids alone, Gemcitabine arrested the growth, 
but scFv62TRAILLys alone did not (Fig. 43), rather induced a slight increase that was not 
due to the construct itself, but to other components in the preparation, because it was 
also induced by conditioned medium of the CHO-K1 cells used to produce 
scFv62TRAILLys (Fig. 45). When analyzing the whole duration of the experiment (see 
accompanying videos), we observed that tumour cells overgrew the RTL-PSC cells; 
given that these are needed to maintain the spheroid, it was not possible to detect a 
clear, compact spheroid after 50 hours. The effect was more dramatic in the presence 
of gemcitabine, which arrests the growth of RTL-PSC. In this time, the caspase 3-7 
activity measured in the presence of scFv62TRAILLys was larger than with Gemcitabine. 
Nevertheless, the complexity of the system does not allow in reaching solid conclusions 
of these experiments, other than that the construct is also active in 3D cultures.  
 
Figure 42: Arrest of the growth of stellate cells (RLT-PSC mCherry) in 3D 






Figure 44: Reduction in proliferation was detected with the treatment with 
scFv62TRAILLys alone and in combination. 
Figure 43: Reduction in proliferation was observed with the treatment with 













6. Combination therapy reduced the rate of tumour growth in vivo 
 
As the combination treatment of our construct with Gemcitabine in both the 2D and 3D 
in-vitro system showed promise, we wanted to test if this is true even when applied to 
an in-vivo system. To this end we went ahead with applying a treatment strategy on sub 
cutaneous tumour models. 
Figure 46: In vivo testing of our combination therapy demonstrated reduction in 
growth rate:  5x106cells/200L of PBS of Capan-1 was injected into the flanks of the 
each SCID mice. Two weeks after implantation they were treated with Gemcitabine 
(80mg/kg) alone, scFv62TRAILLys (200L/mice) alone or Gemcitabine in combination 




We injected 5x106 Capan-1 cells subcutaneously on the flanks of nude mice. Two 
weeks after implantation the mice were treated with Gemcitabine (80 mg/kg) alone, 
scFv62TRAILLys (200 L/mice) alone or Gemcitabine in combination with 
scFv62TRAILLys for a period of 4 weeks. As observed in Figure 46, which shows the 
tumour volume through the different treatment strategies, treatment with 
scFv62TRAILLys construct in combination with Gemcitabine induced a statistically 
significant decrease in tumour volume compared to controls as well as construct alone. 
Furthermore on combination treatment also had a significant decrease in tumour 
volume when compared to those treated with Gemcitabine alone.  
 
Importantly, as demonstrated by Figure 47, mice grew similarly in terms of body weight 
under all treatments, indicating no significant toxicity of any of the treatments. 
Figure 47: Monitoring the toxicity of the therapy showed no variation in treated 
versus control.  Two weeks after implantation they were treated with Gemcitabine 
(80mg/kg) alone, scFv62TRAILLys (200L/mice) alone or Gemcitabine in combination 





Our study investigated the functional role of Kv10.1 in PDAC and its potential 
therapeutic application. The functional role of the channel was studied in vitro by 
manipulating its expression levels. Due to its aberrant expression in tumours we could 
exploit Kv10.1 as an antigen and design and generate a bi-functional antibody 
recognizing the channel and targeting the apoptosis-inducing TRAIL to the tumour cells. 
We were successful in demonstrating the efficacy of the construct in combination with 
Gemcitabine both in vitro and in vivo in PDAC models.  
The ion channel Kv10.1 is expressed during a short time period in cell division in normal 
tissues, and therefore not detectable (Urrego et al. 2016). In tumours, due to either a 
larger proliferative fraction or a dysregulation of its transcriptional control, Kv10.1 is 
often prominently expressed. Studies involving inhibition of channel function or 
expression in vitro led to a reduction in cell proliferation (Pardo et al. 1999, Weber et al. 
2006, Gomez-Varela et al. 2007) and migration (Hammadi et al. 2012) and reduction in 
tumour progression in vivo (Downie et al. 2008).  
Manipulation of Kv10.1 expression or function has never been done on PDAC cell lines 
to our knowledge. To address this question, we selected five human PDAC cell lines: 
AsPC-1, derived from ascites and poorly differentiated, Capan-1, derived from liver 
metastasis and well differentiated, PANC-1 BxPC-3 and MIA PaCa-2 derived from 
primary tumour and poorly differentiated (Deer et al. 2010).  We went onto test the 
expression levels of Kv10.1 at both the RNA and protein levels (Fig. 11 and Fig. 12) 
Like in essentially all cell lines reported previously, expression of the channel was low, 
but consistently detectable by nested and quantitative real-time PCR. qPCR data 
revealed different expression levels between cell lines (PANC-1≈Capan-1>AsPC-
1>BxPC-3>MIA PaCa-2), but in all cases the expression was low compared to the 
positive control (the neuroblastoma cell line SH-SY5Y) (Fig. 11). The low levels of 
expression could at least in part be due to the fact that the determinations were done in 
asynchronous cultures, and the expression of Kv10.1 is strongly modulated during cell 




To test if this low expression was an indication of a marginal functional contribution of 
Kv10.1 to the phenotype of the cell lines, we set out to test the effects of Kv10.1 
knockdown using siRNA on the proliferation rates of all five cell-lines. It was reasonable 
to hypothesize that this could be the case, since human PDAC was responsive to 
Kv10.1 inhibition in xenograft experiments (Gomez-Varela et al. 2007). Upon transient 
knock down of Kv10.1, AsPC-1 and BxPC-3 showed no change in proliferation rate. 
PANC-1 and Capan-1 showed a significant increase in proliferation, while the only 
significant reduction observed was for the case of MIA PaCa-2, which was the cell line 
with the lowest expression of Kv10.1, but also the one that had highest proliferation 
rates.  
Kv10.1 is also known to influence cell migration (Hammadi et al. 2012). We therefore 
tested if the migration of the five cell lines was affected by transient knockdown of 
Kv101. In this case, only BxPC-3 cells showed an effect by having a decrease in 
migration, but none of the cell lines expressing Kv10.1 more abundantly reduced its 
migration after Kv10.1 knockdown.  
The lack of relevant effects was not due to transient knockdown, at least for Capan-1 
cells. From these cells we were able to generate a stable cell line expressing a shRNA 
targeting Kv10.1. This cell line showed a modest but significant decrease in proliferation 
as compared to the control transduced cell line (transduced with only GFP), but no 
change on migration. 
Similarly, cells stably overexpressing Kv10.1 (PANC-1 and MIA PaCa-2) did not show 
dramatic effects on proliferation; overexpression in Panc1 induced a small increase in 
migration.  
In summary, the modest expression of Kv10.1 detected in the five PDAC cell lines does 
not seem to be crucial for their behavior in vitro, in terms of both proliferation and 
migration. Therefore, it would be unlikely that inhibition of Kv10.1 is a plausible strategy 
in PDAC in general, as it has been proposed for other tumours. Nevertheless, it still can 
be utilized as a marker to target other active molecules to the tumour cells. 
Over the last two decades, antibody based therapy of both solid and haematological 




this kind of therapy is to find antigens specifically overexpressed in human cancers. As 
stated before, Kv10.1 is aberrantly expressed in more than 70% of tumours from 
various origins (Hemmerlein et al. 2006, Ding et al. 2007, Wadhwa et al. 2009, Agarwal 
et al. 2010, Asher et al. 2010). Previous in vitro studies on various cell lines have 
indicated it to be located on the cell surface, which is a requisite for antibody-based 
therapy (Kohl et al. 2011).  
In our study we used an in-house generated construct which comprises a single chain 
antibody specific to the external region of Kv10.1 (scFv62) linked to sTRAIL (Hartung et 
al. 2011). This construct was designed and engineered with a vision to specifically 
target cells harbouring Kv10.1; once scFv62 binds to the target, TRAIL receptors are 
activated inducing apoptosis. Recent studies have shown that although DR4 and DR5 
are apoptosis-inducing receptors, DR5 is the main receptor activated by TRAIL (Reis et 
al. 2009). To further enhance the apoptotic potential of the construct we used a modified 
version that carries a point mutation in TRAIL at position 131 (Glycine to Lysine; 
scFv62TRAILLys). This point mutation increases the affinity of TRAIL towards DR4, but 
does not change its affinity towards DR5, thereby targeting a wider range of cancer cells 
that are sensitive to TRAIL induced apoptosis (Reis et al. 2009).  
The goal of the study was to determine if a combination of scFv62TRAILLys and 
Gemcitabine is able to increase efficacy of the chemotherapeutic drug. Gemcitabine is 
currently used as the first line chemotherapeutic drug for PDAC patients, but renders a 
modest clinical benefit, mainly due the acquisition of chemo-resistance by the tumour. 
To test this, we selected two of the cell lines described above. Capan-1, because it 
shows expression of Kv10.1 in vivo (Fig. 13) and is resistant to sTRAIL (Wicker et al. 
2010), and BxPC-3, which shows little Kv10.1 expression both in vitro and in vivo (Fig. 
13) but is sensitive to sTRAIL alone (Wang et al. 2007).  
In cytotoxicity assays we were able to observe a marked loss of cell viability on the 
PDAC cells upon combination treatment (Gemcitabine + scFv62TRAILLys construct). 
Under our experimental conditions, Gemcitabine alone did not induce significant toxicity. 
Soluble TRAIL alone induced the death of BxPC-3 cells, but not of Capan-1, as 
previously described; also as expected, both cell lines were sensitive to a combination 




both cell lines, and the toxicity was potentiated by combination with Gemcitabine in 
Capan1 (Fig. 10). This is compatible with a scenario where scFv62TRAILLys mimics 
membrane-bound TRAIL, which is usually more efficient in inducing cell death than 
sTRAIL (Muhlenbeck et al. 2000, Kelley et al. 2001, Bremer et al. 2004, Bremer et al. 
2008, ten Cate et al. 2009, de Bruyn et al. 2010); in this way, BxPC-3 cells would die in 
the presence of either sTRAIL or the TRAIL moiety present in the construct, while 
Capan-1 cells would need the presence of Gemcitabine, which in this case would 
preclude apoptosis-escape mechanisms. 
Cell death under treatment occurred through an apoptotic mechanism that implies the 
activation of the caspase cascade pathway. Caspase-3/7 activation was measured by 
fluorescent reporters (Fig. 22 and 23) and western blot (Fig. 25), and apoptosis was 
confirmed by Annexin V binding assays (Fig. 26, 27 and 28). Also in favour of an 
apoptotic mechanism speaks the fact that a short exposure to the agent is enough to 
induce the same degree of caspase activation as a long exposure, but the time course 
is similar in both cases, indicating that the cells enter a no-return path in the first few 
hours and are thereafter committed to apoptosis (Fig. 20). 
When monitoring caspase activity by fluorescence or by cleaved caspase detection,  
BxPC-3 cells that were treated with Gemcitabine in combination with sTRAIL had lower 
caspase activity than those treated with Gemcitabine alone (Fig. 13), even though the 
cytotoxicity was very similar in cells treated with sTRAIL alone or in combination (Fig. 
11). It can also be appreciated that scFv62TRAILLys alone has a higher caspase 3/7 
activation compared to sTRAIL, which in part could be attributed to the mutation 
introduced in TRAIL.  
The activation of the apoptosis cascade by the fusion protein requires TRAIL. A single 
chain antibody (scFv62-Cys) did not produce comparable effects (Fig. 29). 
Recent studies involving use of sTRAIL treatment both in vitro and in vivo have shown 
that TRAIL may in fact have dual role. Besides inducing pro-apoptotic signalling, it leads 
to the activation of other signalling pathways via the secretion of pro inflammatory 
cytokines such as, IL-8 or invasion promoting protein urokinase  (Zhou et al. 2008, Zhou 




that this will be the case when using scFv62TRAILLys. We detected an increase in IL-8 
upon treatment with Gemcitabine alone or in combination (Fig. 38) but we did not detect 
an increase after treatment with scFv62TRAILLys, strongly indicating that, unlike soluble 
TRAIL, our construct does not induce pro-inflammatory response via IL-8.  
Pancreatic stellate cells (PaSc) play a major role in the desmoplastic reaction in PDAC 
(Apte et al. 2004). PaSc and pancreatic cancer cells share a symbiotic relationship and 
influence reciprocally their behaviour. It has been suggested that this could be the 
reason for the increased growth rate of the cancer, possibly metastasis and also the 
cause for chemo-resistance (Pandol et al. 2009). We therefore tested whether co-
culture with PaSc changes the response to scFv62TRAILLys, using red fluorescent 
immortalised PaSc, which could readily be identified and distinguished from tumour 
cells. Stellate cells themselves were insensitive to scFv62TRAILLys and sTRAIL, both 
when cultured alone or in combination. Gemcitabine induced a growth arrest in all 
cases, but did not impair viability. Combination of scFv62TRAILLys with Gemcitabine did 
induce caspase activation after much longer incubation periods that those needed for 
cancer cells. At those late time points, the cultures had already reached confluence, and 
this makes the results difficult to interpret.  
Nevertheless, co-culture with PaSc increased significantly the induction of apoptosis in 
Capan-1 cells by combination of scFv62TRAILLys and Gemcitabine (Fig. 34). 
Intriguingly, this sensitizing effect was only observed in the combination treatment and 
not with Gemcitabine alone, and was also much less evident in BxPC-3 cells (Fig. 36). 
To achieve a more realistic model system in vitro, we next ventured into investigating 
the efficacy of the combination treatment in a 3D culture model. Interestingly, while 
BxPC-3 could form very tight spheroid on their own and even without matrigel, Capan-1 
cells fail to form tight spheroids when cultured alone in matrigel. However, in co-
cultures, stellate cells formed a spheroid around the loosely packed Capan-1 cells. In 
these spheroids it was possible to identify stellate cells by their red fluorescence (Fig. 
39) Treatment with Gemcitabine alone induced the extrusion of the cancer cells from 
the spheroid. This could be interpreted as an outgrowth of cancer cells (almost 
insensitive to Gemcitabine) while PaSCs suffer growth arrest and can no longer contain 




system of only PaSCs. The cancer cells in turn respond by making way out of the 
spheroid into the medium thereby being more reachable and susceptible to the 
treatment, which is reflected in the increase in caspase 3/7 activity.  
These results encouraged us to translate this in an in vivo setting. We evaluated the 
treatment strategy on a sub-cutaneous model of Capan-1 in SCID mice. As expected 
we witnessed a reduction in the growth of the tumours treated with Gemcitabine alone; 
remarkably this reduction was further significantly increased in mice treated with 
scFv62TRAILLys in combination with Gemcitabine, strongly indicating that 
scFv62TRAILLys overcomes resistance to Gemcitabine also in vivo. The treatment did 
not induce major toxicity at the dosage used, and the body weight of mice did not differ 
much between treated and non-treated animals. 
Future work 
The major goal of this study was to investigate and develop a novel targeted 
therapy using Kv10.1 as a tumour marker for PDAC models. Using the first-line 
chemotherapeutic drug Gemcitabine in combination with the bi-functional antibody 
conjugated to TRAIL (scFv62TRAILLys) we are able to provide a potential blueprint for a 
treatment strategy in PDAC patients.   
The study successfully demonstrated in both in vitro and in vivo models the 
efficacy of the construct alone and in combination with Gemcitabine. This has led to a 
path for future experiments that could further expand our knowledge and validate the 
current work.  
Establishing a robust 3D in vitro culture model would give us mechanistic insight 
into the effect of the combination treatment and allow the use of medium- and high-
throughput techniques and perform dose-response determinations to determine the 
concentration of each component that achieves best efficacy with least toxicity. 
Although the in vivo results have been able to confirm the efficacy of the treatment 
additional studies on the tumour histology of the treated mice could enlighten and 
provide more information on changes at the morphologic or genomic level compared to 




Further in vivo models can also be tested to further the understanding on the efficacy of 
the construct. Other models like the orthotopic and transgenic which mimic the patient 
tumour more closely would further characterize this treatment strategy. In vivo models 
with other cell lines such as BxPC-3 could provide with useful insight into the efficacy of 
the drug in tumours that express Kv10.1 sparsely. Lastly, it would be interesting to 
implant both cancer and stellate cells to understand the role stellate cells play in the 
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